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Chapter 1
Introduction
Polycystic liver disease (PLD) is a rare condition characterized by the formation of 
numerous liver cysts.1 It can be present in the combination with renal cysts as a 
manifestation of autosomal dominant polycystic kidney disease (ADPKD),  or isolated as 
autosomal dominant polycystic liver disease (PCLD; Box 1).8 For a long time PCLD and 
ADPKD were assumed to be phenotypic variants, although they now are regarded as 
genetically distinct. As both disorders have polycystic livers in common, they probably 
share pathophysiologic pathways.
Ductal plate malformation
PLD probably results from ductal plate malformation during fetal development.10 The 
ductal plate is the anatomical template for the development of the intrahepatic bile 
ducts.12 A lack of adequate remodeling of the ductal plate during morphogenesis of the 
bile duct leads to persistence of embryonic biliary structures that consist of elongated 
lumina and do not communicate with normal ducts (Figure 1). It is thought that ductal 
Box 1. Underlying genetic diseases in PLD
PCLD
PCLD is rare, with an approximate prevalence of 1:158,000 based on a Dutch cohort 
study.1 It is caused by PRKCSH or SEC63 mutations, although in only ~20% of patients 
a bonafide mutation can be found.2 These genes encode the proteins hepatocystin 
and SEC63, both involved in folding and quality control of glycoproteins in the 
endoplasmatic reticulum.3-5 The LRP5 mutation was recently discovered as a new 
causative gene in PCLD.6 
ADPKD
ADPKD is the most common genetic cause of end-stage renal disease, with a 
worldwide prevalence of 0.1-0.2%.7 ADPKD is inherited in an autosomal dominant 
fashion, and so far two genes, PKD1 and PKD2, have been implicated to cause the 
disease in almost 100% of cases.9 These genes encode two transmembrane proteins, 
polycystin-1 and polycystin-2, which are located at the primary cilium of cells.11  
Figure 1: Embryonic development of the ductal plate. A. During early embryogenesis, a single-layer ductal plate 
surrounds the portal vein. B. Double-layered plates are then formed. C. Resorption of the ductal plate leads 
to the formation of a network of bile ducts. D. Insufficient resorption of the ductal plate leads to large dilated 
segments of the primitive bile duct and is considered to be the cause of cyst formation.
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plate malformations represent the pathological basis of fibro(poly)cystic liver disorders 
such as biliary micro-hamartomas, Caroli’s syndrome, autosomal recessive polycystic 
kidney disease, PCLD and ADPKD.13, 14 
Hepatic cystogenesis
Experimental studies have provided evidence for the presence of cholangiocyte 
hyperproliferation and enhanced fluid secretion in cyst expansion.15 These mechanisms 
are initiated by several signal transduction pathways that are aberrantly activated 
in polycystic livers. First, estrogens and vascular endothelial growth factors are 
overexpressed in hepatic cystic epithelium and promote proliferation of cholangiocytes 
through autocrine and paracrine mechanisms.16, 17 Second, hepatic cysts exhibit markedly 
higher levels of phosphor-mammalian target of rapamycin (mTOR), which suggests that 
the mTOR pathway might modulate growth of liver cysts.18 Third, mTOR controls the major 
transcriptional factor for VEGF (hypoxia-inducible factor-1α) and seems to be essential for 
its proliferative, antiapoptopic and proangiogenic effects.17 Finally, cysts have high levels 
of adenosine 3’,5’ – cyclic monophospate (cAMP), which contributes to cholangiocyte 
proliferation and fluid secretion by activating several cAMP mediators, such as protein 
kinase A.19-21 The elucidation of these pathways involved in hepatic cystogenesis led to 
the development of novel therapeutic approaches in PLD.
Natural course
Hepatic cysts are always present in PCLD, and are highly prevalent in ADPKD (67%-83%).22 
Although genetic and phenotypic differences exist between PCLD and ADPKD, the natural 
history of PLD is to a large extent similar for both disorders.8 The clinical course of PLD 
dictates a continuous progression of size and number of hepatic cysts and is usually 
diagnosed during the fourth or fifth decade of life. The rate of progression is not known 
at this time but data from the Consortium for Radiologic Imaging Studies of Polycystic 
Kidney Disease (CRISP) sheds some insight in the natural history of liver cysts in ADPKD. 
Their study shows that the mean growth of a single liver cyst is about 1,13 ml in one 
year.22 Three recent trials with octreotide and lanreotide in patients with PLD showed an 
annual growth of liver volume of 0.9-3.2%.23-25 PLD tends to be more severe in females as 
they acquire cysts earlier in life and develop more cysts during their lifetime.26 Other risk 
factors for hepatic cyst growth are age, renal cyst volume, severity of renal disease, prior 
pregnancies, and estrogen use.1, 27-29 Indeed, 1 year of estrogen use in postmenopausal 
ADPKD patients selectively increases total liver volume by 7%, whereas total kidney 
volume remains unaffected.30 
Diagnostic criteria
Currently, we lack unified diagnostic criteria for PLD. Abnormalities in liver enzyme levels 
are generally absent, with the exception of γ-glutamyltransferase and alkaline phosphatase 
in severe PLD, and are thus not useful in the diagnostic process.8 At present, the diagnosis 
of PLD is made by imaging and is arbitrarily defined by the presence of more than 20 liver 
cysts as measured by ultrasound, CT or MRI.1 Both underlying disorders of PLD (ADPKD 
and PCLD) have their own radiological diagnostic criteria. While ADPKD is diagnosed 
using the adjusted Ravine criteria, a PCLD diagnosis is made when a polycystic liver is 
present and no fulfilment of aforementioned ADPKD criteria.31 However, in families with 
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isolated PLD, ≥ 4 liver cysts can be sufficient for a PCLD diagnosis.32 Clinical differentiation 
between PCLD and ADPKD as the underlying disease remains difficult in patients without 
a positive family history, as PCLD patients may have a few renal cysts and ADPKD patients 
may possess polycystic livers as a predominant feature. Although mutation analysis is 
rarely performed in routine clinical practice, it can be helpful in these cases. 
Disease severity
The severity and distribution of cysts in PLD can be classified according to the Gigot 
criteria, which categorizes according to number and size of liver cysts and the amount 
of remaining liver parenchyma (Figure 2).33 Patients with <10 large (>10 cm) cysts are 
classified as type I. Type II include patients with diffuse involvement of liver parenchyma 
by multiple medium-sized cysts with remaining large areas of noncystic liver parenchyma. 
In type III massive diffuse involvement of liver parenchyma by small- and medium-sized 
liver cysts and only a few areas of normal liver parenchyma are present.33 Gigot type I 
livers technically do not classify as a polycystic liver, due to the low number of liver cysts. 
Although the Gigot criteria are useful for crude determination of severity of PLD, the 
extent of the disease is at present more accurately assessed by CT or MRI volumetry.24, 
34, 35 A commonly used CT/MRI volumetry method is segmentation, which is the manual 
delineation of transversal CT or MRI images and subsequent interpolation by imaging 
software. Other methods for estimating volumes are stereology-based approaches.24, 36 
Although manual volumetry is very time-consuming (60-90 minutes), it is at present the 
most accurate method to determine liver size, with excellent intra- and interobserver 
variability.23 
Figure 2: Gigot type I–III livers. A. Transverse CT image of Gigot type I cystic liver containing a couple of large 
(>10 cm) cysts, but <10 cysts in total. B. Transverse CT image showing a Gigot type II polycystic liver with 
diffuse involvement of liver parenchyma by multiple medium-sized cysts. C. Transverse CT image of a Gigot 
type III polycystic liver. The liver is completely occupied with numerous cysts, and only few areas of visible liver 
parenchyma are present.
Symptoms
The majority of PLD patients is clinically asymptomatic.26 However, the massive 
hepatomegaly can cause compression of the adjacent gastrointestinal tract, vasculature, 
and diaphragm, resulting in mechanical symptoms. Frequent symptoms associated with 
PLD are abdominal distension, abdominal pain, dyspnea and back pain.1, 29 In addition, the 
severe hepatomegaly can lead to malnutrition due to early satiety, anorexia and vomiting.1, 
37 In general, the capacity of the liver to synthesize proteins remains intact even in severe 
PLD.38 Specifically in ADPKD, highly symptomatic PLD has become more common due to 
reduced cardiovascular mortality, extended renal survival, and increased life expectancy 
of patients on renal replacement therapy.39-41 Complications of PLD include intracystic 
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haemorrhage, rupture of cysts or cyst infection and typically only occur in patients with 
severe PLD.1, 42 Cyst haemorrhage and ruptures can be treated conservatively, whereas 
patients with infected cyst require hospitalization with intravenous administration of 
antibiotics.43, 44 In rare cases, strategically located hepatic cysts can cause hepatic venous 
outflow obstruction, portal hypertension or obstructive jaundice.1, 29, 45, 46  There are several 
generic questionnaires available that assess gastrointestinal symptoms in patients.47-51 At 
this moment, there is no standard validated questionnaire that scores symptoms in PLD. 
Therapy
Treatments options in PLD depend on the severity of the phenotype and on the presence 
of symptoms. If the phenotype is limited, PLD can be managed conservatively. The 
progression in most patients will necessitate a therapeutic intervention over time. In 
patients with dominant cysts percutaneous cyst aspiration and alcohol sclerosis is a 
good option.34 In more advanced cases cyst fenestration35, partial hepatectomy, and 
even liver transplantation may be indicated.52 The choice of treatment depends on the 
extent, distribution, and anatomy of the cysts. So far, no preventive therapy exists for 
PLD. Several pharmacological options for PLD have been investigated. These drugs aim to 
reduce hepatic and renal volume, and in this respect somatostatin analogues appear to 
be the most promising. 
Somatostatin analogues
The somatostatin analogues lanreotide and octreotide bind to somatostatin receptors 
2, 3 and 5, which are widely expressed in many tissues including cholangiocytes.53-55 To 
date, the exact spectrum of somatostatin receptor expression in polycystic liver epithelia 
is unknown. These long-acting agents reduce intracellular levels of cAMP by activating 
signalling cascades through the G
i
 α subunit, thereby inhibiting cholangiocyte proliferation 
and preventing fluid accumulation in liver cysts in vitro and in vivo. Indeed, in rats with 
inherited polycystic livers (PCK rats) octreotide treatment caused significant reductions in 
liver weight (-22%) and liver cyst volume (-39%), indicating that octreotide can suppress 
liver cyst growth.55  In our center, we performed a trial with the long-acting somatostatin 
analogue lanreotide. In this multicenter, randomized, double-blind, placebo-controlled 
trial, we randomly assigned 54 patients with PLD to either lanreotide 120 mg or placebo, 
administered every 28 days for 24 weeks. Lanreotide reduced liver volume in PLD 
patients. Mean liver volume decreased from 4606 to 4471 mL with lanreotide, (-2.9%) 
while in placebo volume increased by 1.6%.23 Two other studies demonstrated that 40 
mg of long-acting octreotide monthly decreased liver volumes with 4.4% and 5.0% after 
respectively 6 and 12 months, whereas liver volume increased by 1.2% and 0.9% in the 
placebo arms.24, 25 Side-effects of somatostatin analogues included steatorrhea, diarrhea, 
abdominal cramps and flatulence and were well tolerated in the trials. Although the effect 
of somatostatin analogues seems consistent between the trials, there was considerable 
variability in treatment response between included patients (Figure 3).
Gaps in our knowledge
The initial discovery by our group that somatostatin analogues decrease polycystic liver 
volumes has created a new field of therapeutic options in PLD (Chapter 2). However, 
there are still some issues that need to be resolved before somatostatin analogues can 
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be used in daily practice. A more pronounced side-effect profile can possibly off-set the 
potential benefits of somatostatin analogue therapy and thereby limiting its use in certain 
subgroups of PLD patients . In the same vein, the wide range of liver volume reductions in 
the clinical trials suggests there may be subgroups of patients with increased responses 
to somatostatin analogue therapy.23 Given the expense involved and the overall modest 
effect of somatostatin analogues in trials, it is clear that we have to investigate whether 
there are subgroups of PLD patients who will benefit more from this therapy. We 
hypothesize that certain patient factors (age, gender), disease characteristics (underlying 
diagnosis, liver size, lab abnormalities) or treatment variables (somatostatin analogue 
type) may affect outcomes in PLD patients receiving somatostatin analogue therapy. By 
addressing these issues, we will identify factors associated with worse prognosis, lower 
occurrence of side-effects or with better treatment responses in PLD. These findings will 
help us to individualize treatment in PLD patients, thereby preventing unnecessary or 
ineffective somatostatin analogue therapy.
The aim of this thesis is to identify which patients with polycystic liver disease will 
benefit from somatostatin analogue therapy, in order to develop an individualized, 
evidence-based treatment approach for these patients. We composed two research 
questions in order to answer the aim of this thesis.
Figure 3: Percent changes in liver volume for all treatment periods including in the three placebo-controlled 
trials that evaluated somatostatin analogues in PLD. Each bar represents 1 treatment period (n=119).
Research question 1: Are somatostatin analogues effective and safe in ADPKD patients?
Three randomized trials have demonstrated that somatostatin analogues decrease liver 
volume in mixed populations of patients with autosomal dominant polycystic kidney 
disease (ADPKD) and isolated PLD (described in more detail in chapter 2).23-25 The chronic 
renal failure associated with ADPKD may influence the effect of somatostatin analogues 
and enhance the risk for adverse events. Our hypothesis is that the somatostatin 
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analogue lanreotide reduces total liver volume and total kidney volume, improves 
symptoms and health-related quality of life and has an acceptable safety profile in ADPKD 
patients.  To investigate our hypothesis, we designed an observational trial that included 
43 ADPKD patients with PLD. The primary outcome was change in total liver volume 
after 24 weeks of lanreotide therapy. Secondary outcomes were change in total kidney 
volume, renal function, gastrointestinal symptoms measured by the GIS and quality of life 
measured by the EuroQol-5D (EQ-5D).56 We also include a standardized gastro-intestinal 
symptoms (GIS) questionnaire to assess the presence of gastrointestinal symptoms.47 
This questionnaire also included a visual analog scale (VAS) specific for abdominal pain. 
The EQ-5D is a health-related questionnaire that consists of five dimensions (mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression) and a health state 
assessment on a VAS scale (EQ-VAS). Each of the five dimensions can take one of three 
responses (no/some/severe limitations).56 Chapter 3a describes the rationale and design 
of this trial, whereas Chapter 3b reports on the findings. We chose an observational 
design because it was not ethical to withhold a possible effective therapy from these 
symptomatic patients (principal of equipoise). Observational studies may be critiqued 
because they are thought to overestimate treatment effects.  A formal study comparing 
outcomes of randomized and observational studies concluded that the latter study model 
neither over- nor underestimate treatment effects to any significant degree.57 Although 
this design precluded direct comparison with untreated ADPKD patients, the results were 
directly applicable to clinical practice in real life. 
Research question 2: Are there certain patient or disease groups with increased 
responses to somatostatin analogue therapy?
The large difference in individual responses to somatostatin analogues suggests that there 
are subgroups with increased response to somatostatin analogue therapy. We therefore 
performed an individual patient data meta-analysis including all trials that compared 
somatostatin analogues with placebo in PLD and had liver volume as the primary 
outcome.23-25 The results of this study are discussed in Chapter 4. We hypothesize that 
the efficacy of somatostatin analogues on polycystic liver volume may vary in specific PLD 
subgroups based on underlying diagnosis, sex, age, and liver size. We chose to perform 
a meta-analysis on individual patient data, to achieve the highest grade of evidence. 
Indeed, study level meta-analyses may be adequate when estimating a singled pooled 
treatment effect or investigating study level characteristics, but they can lead to biased 
assessments and have limitations in explaining heterogeneity. Analyses of individual 
patients’ data offer improved statistical power to investigate whether treatment effects 
are related to the patient. 
In addition, the large variety in treatment responses makes it difficult to predict which 
patients have the most reduction in liver volume during somatostatin analogue therapy. 
By identifying patients that have a high chance for responding, we can spare other 
patients from undergoing unnecessary and costly somatostatin analogue therapy. We 
hypothesized that certain patient, disease or treatment characteristics predicted liver 
volume reduction in PLD patients receiving somatostatin analogue therapy. We pooled 
the individual patient data of 4 trials that investigated somatostatin analogues in 
patients with PLD. We included 153 patients that were treated with lanreotide 120 mg or 
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octreotide 40 mg for 6-12 months. Only patients with symptomatic or severe PLD were 
included, in order to represent the population that requires treatment in clinical practice. 
The results of this study are described in Chapter 5.
Finally, we completed the thesis by a general discussion and future perspectives in Chapter 
6. This chapter summarizes our results and discusses the future role of somatostatin 
analogues in patients with PLD.
Reference list
1. Van Keimpema L, de Koning DB, van Hoek B, et al. Patients with isolated polycystic liver disease 
referred to liver centres: clinical characterization of 137 cases. Liver Int 2011;31:92-98.
2. Waanders E, Venselaar H, te Morsche RH, et al. Secondary and tertiary structure modeling 
reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet 
2010;78:47-56.
3. Davila S, Furu L, Gharavi AG, et al. Mutations in SEC63 cause autosomal dominant polycystic liver 
disease. Nat Genet 2004;36:575-577.
4. Drenth JP, te Morsche RH, Smink R, et al. Germline mutations in PRKCSH are associated with 
autosomal dominant polycystic liver disease. Nat Genet 2003;33:345-347.
5. Janssen MJ, Waanders E, Woudenberg J, et al. Congenital disorders of glycosylation in hepatology: 
the example of polycystic liver disease. J Hepatol 2010;52:432-440.
6. Cnossen WR, Te Morsche RH, Hoischen A, et al. Whole-exome sequencing reveals LRP5 mutations 
and canonical Wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci U S A 
2014;111:5343-5348.
7. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 
2009;76:149-168.
8. Drenth JP, Chrispijn M, Nagorney DM, et al. Medical and surgical treatment options for polycystic 
liver disease. Hepatology 2010;52:2223-2230.
9. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009;60:321-337.
10. Desmet VJ. Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities. 
Mayo Clin Proc 1998;73:80-89.
11. Yoder BK. Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol 
2007;18:1381-1388.
12. Strazzabosco M, Fabris L. Development of the bile ducts: essentials for the clinical hepatologist. J 
Hepatol 2012;56:1159-1170.
13. Drenth JP, Chrispijn M, Bergmann C. Congenital fibrocystic liver diseases. Best Pract Res Clin 
Gastroenterol. 2010;24:573-584.
14. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. 
Gastroenterology 2004;127:1565-1577.
15. Strazzabosco M, Somlo S. Polycystic liver diseases: congenital disorders of cholangiocyte signaling. 
Gastroenterology 2011;140:1855-1859.
16. Onori P, Franchitto A, Mancinelli R, et al. Polycystic liver diseases. Dig Liver Dis 2010;42:261-271.
17. Spirli C, Okolicsanyi S, Fiorotto R, et al. Mammalian target of rapamycin regulates vascular 
endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 
2010;51:1778-1788.
18. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc 
Nephrol 2008;19:631-638.
19. Banales JM, Masyuk TV, Gradilone SA, et al. The cAMP effectors Epac and protein kinase a (PKA) are 
involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney 
disease (ARPKD). Hepatology 2009;49:160-174.
20. Spirli C, Locatelli L, Fiorotto R, et al. Altered store operated calcium entry increases cyclic 
3’,5’-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 
phosphorylation in polycystin-2-defective cholangiocytes. Hepatology 2012;55:856-868.
17
General Introduction
1
21. Spirli C, Morell CM, Locatelli L, et al. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/
ERK signaling in polycystin-2 defective mice treated with Sorafenib. Hepatology 2012;56:2363-2374.
22. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early 
autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of 
Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006;1:64-69.
23. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic 
liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009;137:1661-1668.
24. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for 
autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-1061.
25. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin 
analogue octreotide. Clin.J.Am.Soc.Nephrol. 2010;5:783-789.
26. Qian Q, Li A, King BF, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 
2003;37:164-171.
27. Chapman AB. Cystic disease in women: clinical characteristics and medical management. Adv Ren 
Replace Ther 2003;10:24-30.
28. Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for the development of hepatic cysts in 
autosomal dominant polycystic kidney disease. Hepatology 1990;11:1033-1037.
29. Hoevenaren IA, Wester R, Schrier RW, et al. Polycystic liver: clinical characteristics of patients 
with isolated polycystic liver disease compared with patients with polycystic liver and autosomal 
dominant polycystic kidney disease. Liver Int 2008;28:264-270.
30. Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates 
hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 
1997;26:1282-1286.
31. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc 
Nephrol. 2009;20:205-212.
32. Qian Q. Isolated polycystic liver disease. Adv Chronic Kidney Dis. 2010;17:181-189.
33. Gigot JF, Jadoul P, Que F, et al. Adult polycystic liver disease: is fenestration the most adequate 
operation for long-term management? Ann Surg 1997;225:286-294.
34. Van Keimpema L, de Koning DB, Strijk SP, et al. Aspiration-sclerotherapy results in effective control 
of liver volume in patients with liver cysts. Dig Dis Sci 2008;53:2251-2257.
35. Van Keimpema L, Ruurda JP, Ernst MF, et al. Laparoscopic fenestration of liver cysts in polycystic liver 
disease results in a median volume reduction of 12.5%. J Gastrointest Surg 2008;12:477-482.
36. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in 
autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206-216.
37. Temmerman F, Missiaen L, Bammens B, et al. Systematic review: the pathophysiology and 
management of polycystic liver disease. Aliment Pharmacol Ther 2011;34:702-713.
38. Fick GM, Gabow PA. Natural history of autosomal dominant polycystic kidney disease. Annu Rev 
Med 1994;45:23-29.
39. Everson GT. Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin Proc 
1990;65:1020-1025.
40. Orskov B, Romming Sorensen V, Feldt-Rasmussen B, et al. Improved prognosis in patients with 
autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2009;5:2034-
2039.
41. Orskov B, Sorensen VR, Feldt-Rasmussen B, et al. Changes in causes of death and risk of cancer in 
Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. 
Nephrol Dial Transplant 2012;27:1607-1613.
42. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl 
J Med. 2006;354:2122-2130.
43. Lantinga MA, Gevers TJ, Drenth JP. Evaluation of hepatic cystic lesions. World J Gastroenterol 
2013;19:3543-3554.
44. Sallee M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic 
kidney disease. Clin J Am Soc Nephrol 2009;4:1183-1189.
45. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. Hepatology 2004;40:774-782.
46. Macutkiewicz C, Plastow R, Chrispijn M, et al. Complications arising in simple and polycystic liver 
cysts. World J Hepatol 2012;4:406-411.
18
Chapter 1
47. Bovenschen HJ, Janssen MJ, van Oijen MG, et al. Evaluation of a gastrointestinal symptoms 
questionnaire. Dig Dis Sci 2006;51:1509-1515.
48. Agreus L, Svardsudd K, Nyren O, et al. Reproducibility and validity of a postal questionnaire. The 
abdominal symptom study. Scand J Prim Health Care 1993;11:252-262.
49. Rey E, Locke GR, 3rd, Jung HK, et al. Measurement of abdominal symptoms by validated 
questionnaire: a 3-month recall timeframe as recommended by Rome III is not superior to a 1-year 
recall timeframe. Aliment Pharmacol Ther 2010;31:1237-1247.
50. Talley NJ, Phillips SF, Melton J, 3rd, et al. A patient questionnaire to identify bowel disease. Ann 
Intern Med 1989;111:671-674.
51. Guyonnet D, Naliboff B, Rondeau P, et al. Gastrointestinal well-being in subjects reporting mild 
gastrointestinal discomfort: characteristics and properties of a global assessment measure. Br J Nutr 
2013:1-9.
52. van Keimpema L, Hockerstedt K. Treatment of polycystic liver disease. Br J Surg 2009;96:1379-1380.
53. Gong AY, Tietz PS, Muff MA, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal 
bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol Cell Physiol 2003;284:C1205-C1214.
54. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
55. Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model 
of polycystic liver disease by reducing cholangiocyte adenosine 3’,5’-cyclic monophosphate. 
Gastroenterology 2007;132:1104-1116.
56. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. 
Health Policy 1990;16:199-208.
57. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl 
J Med 2000;342:1878-1886.
19
General Introduction
1
 
 v
Chapter 2
Somatostatin analogues for treatment of polycystic liver 
disease
Tom J.G. Gevers MD1; Joost P.H. Drenth MD PhD1
1 Department of Gastroenterology and Hepatology, 
Radboudumc, Nijmegen, the Netherlands 
Curr opin Gastroenterol. 2011; 27(3): 294-300
22
Chapter 2
Abstract
Purpose of review
The present review summarizes the existing knowledge on polycystic liver disease and 
highlights the progress made in medical treatment for this condition in the past year.
Recent findings
Polycystic liver disease is associated with autosomal dominant kidney disease (ADPKD) 
and autosomal dominant polycystic liver disease (PCLD). Signaling pathways of adenosine 
3’,5’ – cyclic monophospate (cAMP) and mammalian target of rapamycin (mTOR) are 
aberrantly regulated in polycystic livers and promote hepatic cystogenesis. Somatostatin 
analogues reduce intracellular cAMP, and this might prevent fluid accumulation in hepatic 
cysts. Several clinical trials published over the last year now show that somatostatin 
analogues when given for 6-12 months in patients with ADPKD and PCLD decrease total 
liver volume, attenuate polycystic kidney volume, and improve perception of health. 
In two recent studies mTOR inhibitors failed to halt the progression of ADPKD. It is still 
too early to recommend to start somatostatin analogues in polycystic liver disease and 
definitive answers should come from future  clinical trials. 
Summary
Somatostatin analogues are promising new medical drug options in the treatment of 
polycystic liver disease. However, more needs to be elucidated with regard to molecular 
mechanisms in hepatic cystogenesis, the uncertainty who will respond to therapy and 
long-term outcomes. 
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Introduction
Polycystic liver disease is a rare disorder arbitrarily defined by presence of more than 
20 liver cysts.1 It can be present in the combination with renal cysts as a manifestation 
of autosomal dominant polycystic kidney disease (ADPKD), or isolated in the absence 
of renal cysts as autosomal dominant polycystic liver disease (PCLD).2 For a long time 
PCLD and ADPKD were assumed to be related phenotypic variants, but the discovery of 
causative genes led to the concept that they are  genetically distinct.3, 4 As observed in 
several trials, polycystic liver volumes vary from 1000 ml to over 10 000 ml.5-7 Symptoms 
are related mainly to the size of the liver, and include abdominal distension, dyspnea, 
pain and early satiety.1 Complications are uncommon and include bleeding, rupture 
and infection of cysts.8 So far, no curative or preventive therapy exists for polycystic 
liver disease. Primary treatment goal in polycystic liver disease is reduction of total liver 
volume, as this is thought to relieve symptoms. Most current therapies are invasive and 
consist of surgical removal or at the minimum emptying of cysts.9 Although these surgical 
techniques are fairly effective in treating patients with dominant cysts, their efficacy 
in management of advanced polycystic livers is only moderate.8 Consequently, there is 
a clear need for other therapeutic options. In this article, we will review the advances 
in medical drug treatment of polycystic liver disease as to provide an update on latest 
developments.  
Literature search
We searched the following electronic literature databases: clinicaltrials.gov, the Cochrane 
Central Register of Controlled Trials, and PubMed. All searches were limited to English 
language. We also checked the reference lists of included review articles. In electronic 
searches for efficacy trials, we used following MESH terms ‘polycystic liver disease’ OR 
‘ADPKD’ OR ‘PCLD’. All citations were imported into an electronic database (Reference 
Manager, ISI Researchsoft). The literature search was confined to articles published 
between July 2009 and January 2011. We identified a total of 322 articles that met 
the inclusion criteria. For the purpose of this review we primarily focused on articles 
addressing the role of medical therapy  in management of polycystic liver disease.   
Hepatic cystogenesis 
Liver cysts arise from cholangiocytes and expand due to at least 3 different mechanisms: 
increased cell proliferation and apoptosis combined with neovascularisation; enhanced 
fluid secretion; and abnormal cell-matrix interactions.10  These mechanisms are initiated 
by several signal transduction pathways that are aberrantly regulated in polycystic livers. 
Hepatic cysts exhibit markedly higher levels of phosphor-mammalian target of rapamycin 
(mTOR) and it downstream effectors which contributes to cholangiocyte proliferation and 
subsequent hepatic cyst expansion.11 Furthermore, estrogens, insulin-like growth factor-1 
(IGF-1) and vascular endothelial growth factor (VEGF) are overexpressed in hepatic cystic 
epithelium and promote proliferation of cholangiocytes in an autocrine manner.12 Indeed, 
studies have shown that VEGF signaling pathways are activated in liver cyst epithelia 
and are capable of inducing the growth of cysts in mice, leading to the conclusion that 
VEGF inhibitors might be useful in inhibiting hepatic cystogenesis.13, 14 Finally, adenosine 
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3’,5’ – cyclic monophospate (cAMP) acts as a second messenger in intracellular signal 
transduction and is involved in hepatic cystogenesis by multiple mechanisms. Alterations 
in cAMP stimulate cAMP-dependant chloride and fluid secretion from biliary epithelial 
cells and trigger cholangiocyte proliferation.2 Moreover, secretin, the major cAMP agonist 
in cholangiocytes, stimulates the targeting and insertion of several transporters and 
channels into the apical membrane of cholangiocytes, thereby increasing fluid secretion.2 
This was supported by an elegant experiment demonstrating that intravenous secretin 
administration increases fluid secretion in hepatic cysts from ADPKD patients.15 In view of 
its stimulatory effects on cell proliferation and fluid secretion, targeting cAMP production 
is a promising target for therapeutic intervention in polycystic liver disease. 
Somatostatin analogues  
Somatostatin is a naturally occurring gastrointestinal hormone that regulates various 
endocrine and exocrine processes.16 The half-life of natural somatostatin is less than 3 
minutes, thereby limiting its use in clinical practice. Synthetic somatostatin analogues 
with longer half-lives have been developed to overcome this disadvantage. Somatostatin 
and its synthetic analogues, such as lanreotide and octreotide, bind to somatostatin 
receptors 2, 3 and 5 and suppress intracellular cAMP by activating signaling cascades 
through the Gi protein. Furthermore, somatostatin decreases fluid secretion and cell 
proliferation by reducing cAMP in cholangiocytes.17, 18 In addition, somatostatin blunts 
the release of cAMP agonist secretin.19 In-vivo studies showed that octreotide reduces 
hepatic cyst volume and suppressed hepatic disease in rats by reducing cAMP.10 As a 
consequence, somatostatin analogues are thought to be able to revert the process of 
hepatic cystogenesis by curtailing cAMP accumulation.
Human Studies
Several clinical observations support the use of somatostatin analogues in polycystic liver 
disease. The first cases  describe the effect of  somatostatin analogues in two patients 
with polycystic livers. A 3-month and 6-month therapy led to large reductions in liver 
volume in both patients (14.9 and 38.3%).20 In line with these results, lanreotide 60 mg 
given monthly for 6 months in an ADPKD patient was accompanied by almost a 10% 
reduction in liver volume (Figure 1). Furthermore, another case-report documented  that 
12 months of octreotide in a patient with ADPKD reduced total hepatic and renal cyst 
volume by 6.3 and 8%.21 Interestingly, a large cyst in the left breast from this patient 
also responded (-51%). This suggests that cyst fluid accumulation in different organs is 
a general, dynamic process which can be reversed by somatostatin analogues. A larger 
cases series in eight patients (seven ADPKD and one PCLD) with short-acting octreotide 
100 µg three times a day subcutaneously for a median of 135 days resulted  in a median 
3.0% decrease in liver volume.22 Unfortunately, due to absence of a control group, 
accurate comparison with the natural course of the disease was not possible. 
These observational studies support the principle that somatostatin analogues are able 
to reduce liver volume in polycystic liver disease. However, these studies do not address 
the pertinent question how large the effect really is and which drug at which dosage 
should be used for which duration. 
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Clinical trials with somatostatin analogues
Encouraged by the results of the case studies mentioned above, researchers designed 
several randomized clinical trials to evaluate the effect of somatostatin analogues in 
polycystic liver disease (Table 1). All trials included patients with ADPKD or PCLD and 
used the difference in total liver volume as measured by computed tomography (CT) 
or magnetic resonance imaging (MRI) as a primary endpoint. The first trial treated 54 
patients with severe polycystic livers as the result of ADPKD (n=32) of PCLD (n=22) with 
monthly injections of lanreotide 120 mg for 6 months. Liver volume decreased by 2.9% in 
the lanreotide group, but increased by 1.6% in the placebo group.5  The volume reducing 
effect of lanreotide was also observed with other somatostatin analogues, for example 
octreotide. One trial evaluated the effect of long-acting octreotide 40 mg given monthly 
for a year in 42 patients with ADPKD (n=34) or PCLD (n=8).6 The mean liver volume 
decreased by 5.0% in patients given octreotide, whereas in the placebo group liver 
volume remained practically unchanged (+0.9%). These results were supported by a post 
hoc analysis of data from a randomized, cross-over study in 12 patients with ADPKD.26 
In this analysis, octreotide 40 mg given monthly for 6 consecutive months reduced liver 
volume by 4.5%, whereas treatment with placebo resulted in 0.9% increase in liver 
volume.7 Remarkably, this reduction with octreotide was fully explained by a reduction in 
parenchyma rather than cyst volume. However, no definite conclusions about the effect 
of octreotide on hepatic cyst volume can be drawn from this study, as baseline liver cyst 
volumes were very low. Collectively, these clinical trials raise a number of interesting 
implications: the  beneficial  effect is similar for patients with ADPKD and PCLD and larger 
livers had larger reductions with octreotide or lanreotide than smaller livers. 
Figure 1: Reduction of liver volume following 
somatostatin therapy in an ADPKD patient.
This picture shows an abdominal CT scan of 
an ADPKD patient who received lanreotide 
60 mg for six months. Liver volume on 
panel A was 2.1L which decreased to 
1.9L (panel B), a decline of almost 10%.
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Table 1. Overview of characteristics and results of randomized controlled trials evaluating somatostatin 
analogue or mTOR inhibitor therapy in patients with ADPKD or PLCD
Liver: 4648 Liver: - 2.9 Liver: + 1.6
Kidney: 1058 Kidney: - 1.5 Kidney: + 3.4
Liver: 5730 Liver: - 5.0 Liver: + 0.9
Kidney: 1030 Kidney: + 0.3 Kidney: + 8.6
Liver: 1608 Liver: - 4.5 Liver: + 0.9
Kidney: 2435 Kidney: + 2.2 Kidney: + 5.9
Perico23 Sirolimus
randomized, 
crossover
15 ADPKD/PCLD 6 3 mg daily TKV change, CT Kidney: 1874 Kidney: + 2.2 Kidney: + 3.7
Serra24 Sirolimus RCT 100 ADPKD 18 2 mg daily Percent TKV, MRI Kidney: 955b Kidney: + 10.9 Kidney: + 9.7
Walz25 Everolimus RCT 433 ADPKD 24 5 mg daily TKV change, MRI Kidney: 1968 Kidney: + 11.3 Kidney: + 15.8
a secondary post-hoc analysis performed on data of this crossover study; b volume in cm 3. RCT, randomized controlled trial; TLV, total l iver volume; TKV, total kidney volume.
Percent TLV change, MRI
Caroli7 Octreotide
randomized, 
crossovera
12 ADPKD 6 40 mg monthly TLV change, CT
6
120 mg 
monthly
TLV change, CT
Hogan6 Octreotide RCT 42 ADPKD/PCLD 12 40 mg monthly
Treatment 
regimen
Primary End point
Mean baseline 
volume (ml)
change in baseline 
volume in treatment 
group (%)
change in baseline 
volume in placebo 
group (%)
Van Keimpema5 Lanreotide RCT 54 ADPKD/PCLD
Study Study drug Design Patient (n)
Study 
population
Treatment 
duration 
(months)
The dose of 120 mg lanreotide used in one study5 was equivalent to 60 mg of octreotide, 
which was higher than the 40 mg of octreotide used in the other studies.6, 7 However, as 
lanreotide has a lower affinity for the somatostatin receptor than octreotide, treatment 
doses were probably comparable between all trials.27
 
Renal Volume
Somatostatin analogues also have a positive outcome on polycystic kidneys in patients 
with ADPKD (Table 1). In one trial lanreotide reduced kidney volume by 1.5%, compared 
to 3.4% with placebo.5 In contrast, trials that used octreotide showed slow polycystic 
kidney growth (0.3 and 2.2%) rather than volume reduction in comparison to placebo 
(8.6 and 5.6%).6, 7 One trial reported that these observed effects on kidney volumes were 
strongly correlated to the change in liver volume.7
Side effects
Overall, treatment with somatostatin analogues is well tolerated. Most common side-
effects are mild diarrhea with loose, pale stools and abdominal cramps, which appear 
after the first injections but disappear with prolonged use. Injections site granulomas 
were reported in patients receiving lanreotide or octreotide, with no occurrence in 
placebo groups.5, 6 All patients considered the three times daily injection with octreotide 
regimen used in one trial as very intensive and difficult to continue, thus, the use of long-
acting somatostatin is preferable.22 
Perception of health
Two trials reported that the positive effect of somatostatin analogues was associated 
with a significant improved perception of general health.6, 7 However, as pointed out 
in an accompanying editorial, the high frequency of gastrointestinal side-effects in 
somatostatin analogue treated patients may have compromised  the actual blinding in 
this self-reported analysis.28
mTOR inhibitors
mTOR inhibitors have been used in renal transplant patients as a part of an alternative 
long-term immunosuppressive regimen and have strong anti-proliferative effects.29 There 
is convincing preclinical data suggesting aberrant activation of the mTOR pathway in the 
pathogenesis of ADPKD.30 Sirolimus, a mTOR inhibitor, reduces renal cyst growth, fibrosis 
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and proliferation in several different human-orthologous mouse models of polycystic 
kidney disease.31-33 These observations set the stage for three clinical trials evaluating 
the effect of mTOR inhibitors on kidney volume in patients with ADPKD. The results of 
these trials, however, were disappointing (Table 1). A 2-year placebo-controlled trial 
evaluated whether everolimus, a mTOR inhibitor, would decrease total kidney volume in 
433 patients with ADPKD with stage II or III chronic kidney disease.25 While everolimus 
slowed the increase in total kidney volume, it did not slow the progression of renal 
impairment, indicating that decreasing kidney volume does not necessarily improve renal 
function. Another trial observed that 18 months of treatment with sirolimus in patients 
with early-stage ADPKD failed to slow renal enlargement.24 In addition, a cross-over study 
compared the effect of 6 months sirolimus to conventional therapy on progression of 
ADPKD. This study showed no differences in kidney growth, although the study was 
too small to draw definite conclusions.23 The latter two trials only included early-stage 
ADPKD patients, and no differences in renal function were observed between the two 
treatment arms. Unfortunately, none of these trials included a formal evaluation of liver 
size. It would be interesting to determine the effect of mTOR inhibitors on polycystic liver 
volume, as sirolimus given for 19.4 months in a series of 16 ADPKD patients following 
renal transplantation significantly reduced polycystic liver volume by 11.9%.11 
mTOR inhibitor safety
The largest problem of mTOR inhibitors is the toxicity of the drug precluding its long-term 
use in a population that is relatively healthy and have few preexistent symptoms.23, 34 In 
addition, the dose of sirolimus used in the trials above might be inadequate to achieve 
mTOR inhibition in cysts.35 Limiting side-effects while achieving adequate inhibition of 
mTOR remains a challenge with mTOR inhibitor therapy. 
Future therapeutic strategies
Other therapeutic strategies in polycystic liver disease are specific inhibitors of VEGF, IGF-
1 or estrogens, as these growth factors promote cholangiocyte proliferation and hepatic 
cystogenesis.12, 14 Furthermore, a recent study showed that pioglitazone, a PPARγ agonist, 
attenuates hepatic and renal cyst growth in a PCK rat model.36 Finally, experimental 
evidence demonstrates that miRNAs (i.e., miR-15a) influence cholangiocyte proliferation 
and hepatic cyst growth by affecting the expression of the cell cycle regulator, Cdc25A.37 
These studies lay a framework for the development of new therapies aimed at preventing 
hepatic cystogenesis in patients with polycystic liver disease.
Strategies for the design of future clinical trials
There are still many questions to be answered. Little is known about the optimal dose of 
somatostatin analogues in treatment of polycystic liver disease. Somatostatin analogues 
are well tolerated, and higher doses may lead to more reduction in liver volume without 
an increase in frequency of side-effects. In addition, due to absence of long follow-up 
studies, it is still unknown how long the effects of somatostatin analogues will persist 
after treatment cessation. In a patient who received short-acting octreotide for 90 days, 
liver volume increased back to baseline at 3 months follow-up after a reduction of 9,4%, 
suggesting that long-term treatment is necessary.22 It is now most important to determine 
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whether the long-term use of somatostatin analogues is safe and if the volume reducing 
effect is maintained by prolonged therapy. Experiments in a rat model suggested that the 
beneficial effects of octreotide are time-dependent and dose-dependent, indicating that 
longer duration of therapy might result in more substantial effects.10 In addition, long-
term studies in patients with acromegaly have shown that treatment with somatostatin 
analogues up to 4 years is well tolerated, suggesting that longer treatment with 
somatostatin is feasible.38 Finally, individual patient factors that predict better treatment 
response should be explored. Currently, it is too early to recommend that patients with 
polycystic liver disease start with somatostatin analogues and these should only be used 
in clinical trials.
Ongoing future trials
There are several ongoing trials using somatostatin analogues in patients with polycystic 
liver disease (Table 2). The ALADIN trial (NCT00309283) evaluates the effect of long-
acting somatostatin on kidney volume for 3 years in patients with ADPKD. Furthermore, 
we initiated a randomized, controlled trial (ELATE study, NCT01157858) to assess the 
effect of combined octreotide-everolimus therapy on liver volumes in symptomatic 
polycystic liver patients. These results will be available in 2011. As none of mTOR inhibitor 
trials estimated the effect on total liver volume, its role in polycystic liver disease still has 
to be elucidated.23-25 Two trials (NCT01223755 and NCT01009957) are now ongoing to 
Study name Study number Study drug Study populationStudy design Eligibility Patients (n)
Treatment duration 
(months) Primary end point Completion Date
Single center, 
randomized, 
Age > 18  
single blind GFR > 40 
Age 18 to 70
GFR > 60 December 2011
Symptomatic
Age > 18 December 2013
GFR 15-40
Age > 18
GFR 30-60
December 2012
GFR, glomerular ﬁltration rate; TKV, total kidney volume; TLV, total l iver volume.
GFR change (secondary end 
point, TKV/TLV, CT)
PolEver  NCT01009957 Everolimus ADPKD
Single center, 
open label, 
randomized
90 24
Reduction of GFR 
(secondary end point, l iver 
cyst change, MRI)
12 Percent TLV change, CT
SIRENA-II  NCT01223755 Sirolimus ADPKD
Single center, 
open label, 
randomized
40 36
ELATE study NCT01157858
Everolimus + 
Octreotide PCLD
Single center, 
open label, 
randomized 
44
ALADIN trial NCT00309283
Long-acting 
Somatostatin ADPKD 66 36 TKV change, MRI June 2011
Table 2: Most important ongoing clinical trials using somatostatin analogues or mTOR inhibitors in patients 
with ADPKD or PCLD
evaluate mTOR inhibitors in patients with ADPKD and use liver (cyst) volume change as 
a secondary endpoint (Table 2). However, the disappointing results of recently published 
trials on mTOR inhibitors in patients with ADPKD and its poor tolerability in this population 
clearly demonstrate that there is still a tough road ahead for the use of mTOR inhibitors 
in polycystic liver disease.
Conclusion
In summary, considerable progress toward alternative medical therapies for polycystic 
liver disease has been made. Several clinical trials have shown that it is possible to 
reduce polycystic liver volume and attenuate polycystic kidney volume with somatostatin 
analogues. In contrast, two recent studies evaluating the effect of mTOR inhibitors on 
polycystic kidney volume in ADPKD were not encouraging. It is paramount that well 
designed future studies in this field evaluate the efficacy of prolonging or combining 
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medical therapies in polycystic liver disease. In addition, further unraveling of molecular 
mechanisms in hepatic cystogenesis will aid in the identification of new therapeutic 
strategies. 
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Abstract 
Background 
A large proportion of patients with autosomal dominant polycystic kidney disease 
(ADPKD) suffers from polycystic liver disease. Symptoms arise when liver volume 
increases. The somatostatin analogue lanreotide has proven to reduce liver volume in 
patients with polycystic liver disease. However, this study also included patients with 
isolated polycystic liver disease (PCLD). The RESOLVE trial aims to assess the efficacy of 
lanreotide treatment in ADPKD patients with symptomatic polycystic livers. In this study 
we present the design of the RESOLVE trial. 
Methods/design 
This open-label clinical trial evaluates the effect of 6 months of lanreotide in ADPKD 
patients with symptomatic polycystic livers. Primary outcome is change in liver volume 
determined by computerised tomography-volumetry. Secondary outcomes are changes 
in total kidney volume, kidney intermediate volume and renal function. Furthermore, 
urinary (NGAL, α1-microglobulin, KIM-1, H-FABP, MCP-1) and serum (fibroblast growth 
factor 23) biomarkers associated with ADPKD disease severity are assessed to investigate 
whether these biomarkers predict treatment responses to lanreotide. Moreover, safety 
and tolerability of the drug in ADPKD patients will be assessed. 
Discussion 
We anticipate that lanreotide is an effective therapeutic option for ADPKD patients with 
symptomatic polycystic livers and that this trial aids in the identification of patient related 
factors that predict treatment response. 
Trial registration number 
Clinical trials.gov NCT01354405 
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Background 
Autosomal dominant polycystic kidney disease (ADPKD) most often presents a kidney 
phenotype with hypertension and renal failure due to continuous growth of renal cysts. 
It affects all ethnic groups and has an incidence of 1:500 to 1:1000. 1 ADPKD is inherited 
in an autosomal dominant fashion, and so far two genes, PKD1 and PKD2, have been 
implicated to cause the disease.2 
A large proportion of ADPKD patients suffers from polycystic liver disease, often while 
renal function capacity is preserved. 3 The natural course of polycystic liver disease dictates 
a continuous progression of size and number of hepatic cysts.4, 5 The rate of progression 
is still unknown at his time, but recent trials showed that liver volume increases with 0.9-
1.6% within one year.6-8 
Most ADPKD patients with polycystic liver disease are asymptomatic until significant 
hepatomegaly develops. Subsequently mechanical complaints such as abdominal 
distension, pain, and early satiety arise.9, 10 Other complications include intracystic 
hemorrhage or rupture of cysts causing acute abdominal pain. Currently available 
treatment options aim at reduction of liver volume and are mainly surgical.11 However, 
drawbacks of surgical therapy are the partial effectiveness, their inherent morbidity and 
mortality and their inability to change the natural course of the disease. 
This has led to the introduction of somatostatin analogues as a medical treatment option 
for polycystic liver disease. Somatostatin analogues, such as lanreotide and octreotide, 
are thought to decrease polycystic liver volume through their virtue of cAMP repression.12, 
13 We recently performed a trial with the somatostatin analogue lanreotide in polycystic 
liver patients with autosomal dominant polycystic liver disease (PCLD; isolated polycystic 
liver disease) or ADPKD.8 In this trial, 54 patients were randomly assigned to lanreotide 
or placebo and treated for 6 months. Lanreotide decreased liver volume with 2.9%, 
while it increased by 1.6% with placebo. Moreover, there was a trend of delayed growth 
of polycystic kidney volume in the 32 ADPKD patients that participated. Others trials 
showed similar effects in reducing polycystic liver volume with octreotide.6, 7, 14 These 
observations clearly support the thesis that polycystic liver volume can be reduced by 
somatostatin analogues. 
However, the majority of these trials included a mixture of ADPKD and PCLD patients. 
It is still unknown if these patient groups have divergent responses to treatment with 
somatostatin analogues. To eliminate this possible confounding factor, we have designed 
and initiated a clinical trial (RESOLVE trial) to examine the effectiveness (change in total 
liver volume) of lanreotide in ADPKD patients with polycystic livers. In addition, we will 
determine the effect of lanreotide on change in total kidney and kidney intermediate 
volume. Intermediate volume is tightly correlated with glomerular filtration rate (GFR) 
and its long-term decline, and may represent a marker for ADPKD progression.15 Finally, 
multiple sets of urinary (NGAL, α1-microglobulin, KIM-1, H-FABP, MCP-1) and plasma 
(fibroblast growth factor 23 (FGF23)) biomarkers have been discovered that are correlated 
to parameters of ADPKD disease severity, and may be associated with treatment response 
to lanreotide.16, 17 In conclusion, using the dataset that is generated by the RESOLVE trial, 
we want to assess (1) whether lanreotide has a beneficial effect on growth of polycystic 
liver volume, (2) on growth of total kidney and intermediate volume, (3) on renal function, 
and (4) whether the suggested biomarkers predict treatment responses to lanreotide.
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Methods/design 
Study aim 
The primary objective of the RESOLVE trial is to determine the effectiveness of lanreotide 
to attenuate growth of liver volume in ADPKD patients with symptomatic polycystic livers. 
ADPKD patients with polycystic livers will receive lanreotide 120 mg every 4 weeks for a 
total of 24 weeks (Figure 1). Secondary objectives are to assess the effect of lanreotide 
treatment on total kidney and kidney intermediate volume, to follow renal function and 
to identify biomarkers that predict treatment response. Finally, safety and tolerability of 
lanreotide treatment in ADPKD patients will also be assessed. 
Study population 
ADPKD patients with symptomatic polycystic liver disease Gigot type II (diffuse medium-
size cysts; hepatic parenchyma preserved) or Gigot type III (massive, diffuse small- and 
medium-size cysts; little hepatic parenchyma preserved) between 18 and 70 years are 
eligible for participation of the study.18 Symptomatic patients are defined as having at 
least three of the following symptoms: 
•	 Abdominal pain 
•	 Abdominal distension 
•	 Abdominal fullness 
•	 Dyspnoea 
•	 Early Satiety 
•	 Back pain 
•	 Nausea or vomiting 
•	 Anorexia 
•	 Weight loss 
•	 Jaundice 
The diagnosis of ADPKD is based upon the Ravine criteria.19 Furthermore, patients must 
have an estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal 
Disease (MDRD) above 30 ml/min/1.73 m2.20 The specific study inclusion and exclusion 
criteria are listed below. 
Inclusion criteria: 
•	 Age 18 to 70 years 
•	 Adult subjects with a diagnosis of ADPKD and at least a symptomatic polycystic 
liver Gigot type II 18 
•	 eGFR > 30 ml/min/1.73m2 (MDRD formula) at screening 
•	 Subjects are willing and able to comply with the study drug regimen and all 
other study requirements 
•	 Signed informed consent   
Exclusion criteria: 
•	 History of renal transplantation 
•	 Use of oral contraceptives or estrogen suppletion 
•	 Pregnancy or breastfeeding 
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•	 History of cardiac or pulmonary disease, symptomatic gallstones, pancreatitis or 
diabetes mellitus 
•	 Intervention (aspiration or surgical) targeted at hepatic or renal cysts within 
three months of baseline 
•	 Treatment with somatostatin analogues within 3 months of baseline 
•	 Mental illness that interferes with the patient ability to comply with the protocol 
•	 Drug or alcohol abuse within one year of baseline 
•	 Increased liver enzymes (2-fold above normal values); exception is an isolated 
elevated gamma-glutamyltransferase or alkaline phosphatase, which occurs 
frequently in polycystic liver disease 
•	 Co-medication with known interaction with lanreotide, like cyclosporine 
Exclusion criteria for the use of iodine based radiocontrast: 
•	 Use of nephrotoxic agents like NSAIDs or diuretics within 24 hours before 
receiving a contrast-enhanced CT-scan 
•	 History of moderate or severe reaction to contrast injection 
•	 History of contrast induced nephropathy 
•	 Treatment with I131 during the course of the trial 
•	 Diagnosis of Morbus Kahler or Morbus Waldenström 
•	 eGFR < 60 ml/min/1.73m2 (MDRD formula) 
Study design and setting
The RESOLVE trial is a single centre open label study in subjects with ADPKD. The trial 
aims to enroll 43 ADPKD patients. The trial design is schematically represented in Figure 
1. All eligible patientsreceive lanreotide 120 mg for a total of 24 weeks. At start and end 
of treatment, total liver and kidney volumes are measured by computer-tomography (CT) 
with contrast media if eGFR (MDRD) is > 60 ml/min/1.73 m2, or without contrast media 
if eGFR (MDRD) is 30–60 ml/min/1.73 m2. In addition, all patients are evaluated at 4 and 
12 weeks after start of treatment. Recruitment has started in July 2011, will last until 
July 2012 and will be completed by July 2013. This study is submitted to clinicaltrials.gov 
(NCT01354405). 
Lanreotide 120 mg/4 weeks
CTCT
Patients without Gigot type II or III
polycystic liver are excluded
Inclusion of eligible 
ADPKD subjects
Screening
Day -28 to Day 0
Baseline
Day 1
Treatment
Day 1 to week 24
End of Treatment
Week 24
Figure 1: RESOLVE trial profile. ADPDK subjects are screened for eligibility, and 43 ADPKD patients with 
symptomatic polycystic liver disease and eGFR > 30 ml/min (MDRD formula) will be included. At day 1, all 
patients undergo CT volumetry of liver and kidneys. Patients without polycystic type II or III livers, as determined 
with CT volumetry, will be excluded from the study. Interval visits are scheduled 4 and 12 weeks after start of 
treatment. After 24 weeks of treatment with lanreotide (6 injections), another CT will be erformed to evaluate 
the change in liver and kidney volume 
38
Chapter 3a
Trial treatments 
All patients will receive long-acting 120 mg Somatuline® (Lanreotide) administered deeply 
subcutaneously every 4 weeks (28 days for a total duration of 24 weeks). Another trial 
documented the efficacy and safety of administration of 120 mg lanreotide in patients with 
polycystic liver disease and demonstrated that this dosage is well tolerated in patients and 
there were no notable drop-outs.8 The most common adverse effect are loose, pale and 
fatty stools which typically start 24 hours after the first injection of lanreotide and lasts 
for 1–4 days. Pancreas enzyme replacement is prescribed to ameliorate these symptoms 
if they persist. In case of lanreotide-associated toxicity, the dose will be reduced with 30 
mg until symptoms disappear. Lanreotide will be administered at the patient’s home by 
a dedicated nursing team. 
Primary outcome 
The primary outcome of the RESOLVE trial is to assess the effect of lanreotide treatment 
on total liver volume in ADPKD patients with symptomatic polycystic liver disease. Primary 
efficacy endpoint is absolute change in liver volume after 24 weeks of treatment with 
lanreotide compared to baseline liver volume. We compare our findings with the natural 
course of polycystic liver growth observed in the trials that evaluated somatostatin 
analogue treatment in PLD patients.6-8 
Secondary outcomes 
The proportional change in liver volume (normalized as percentage) from inclusion 
to week 24 will be assessed as a secondary outcome. Furthermore, other secondary 
outcomes are the change in total kidney volume and that of 3 kidney tissue classes.15 
We will distinguish 3 kidney tissue classes on basis of CT images: cysts, parenchyma, 
and intermediate volume. Intermediate volume represents regions with contrast 
enhancement markedly lower than that of vascularized parenchyma tissue but higher 
than that of cysts, and is correlated to GFR decline.15, 21 In addition, changes in quality 
of life (assessment with EuroQoL questionnaire ) and gastro-intestinal symptoms (using 
a gastrointestinal symptoms questionnaire) will be measured at baseline and at end of 
treatment.22, 23 Renal function will be assessed by using estimation equations (MDRD 
and cystatin C) as well as measured creatinine clearance determined by 24-hour urine 
collection. The frequency and severity of all reported adverse events will be recorded 
at every visit to evaluate the safety and tolerability of treatment with lanreotide. Finally, 
urinary biomarkers (NGAL, α1-microglobulin, KIM-1, H-FABP, MCP-1) and serum FGF23 
will be assessed before and after treatment with lanreotide.16, 17 These biomarkers are 
correlated to parameters of ADPKD disease severity and may predict treatment response 
to lanreotide. As concentration of FGF23 in serum is dependent of vitamin D, parathyroid 
hormone (PTH), calcium and phosphate serum levels, these parameters will also be 
measured at start and end of treatment.
Data collection
Data will be collected into a case record form designed to capture all visit information 
including medical history, results from laboratory analysis and adverse events. Study 
duration for all patients is 25–28 weeks in total, divided in a 1–4 weeks screening phase 
and a 24 weeks follow up phase after start of lanreotide (Figure 1). At screening, a 
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pregnancy test is performed (for women with childbearing potential). Within the follow 
up phase of the trial, patients are seen at week 0, 4, 12 and 24. During each visit, medical 
history, adverse events, tolerability and drug accountability are assessed. In addition, 
vital signs and weight are measured, blood samples are drawn and the eGFR (MDRD) is 
estimated. Two main study visits including CT volumetry (procedure described below), 
questionnaires, 24 hour and spot urine collection will take place at start (week 0) and 
end of treatment (week 24). Furthermore, blood and urine samples will be taken for 
assessment of serum FGF23, PTH, Vitamin D, Cystatin C and the urinary biomarkers. The 
requested parameters at the different visits are listed below. 
Screening 
•	 Written informed consent 
•	 Eligibility criteria check 
•	 Estimated GFR (MDRD) 
•	 General characteristics 
•	 Concomitant therapy and medical history 
•	 Physical examination and vital signs 
•	 Laboratory tests: hematology, biochemistry and lipid profile 
•	 Pregnancy test in females between 18-50 years 
Baseline (week 0) and end-of-treatment (week 24) 
•	 CT liver and kidney volumetry 
•	 Estimated GFR (MDRD and Cystatin C clearance) 
•	 Creatinine (24-hour urine) 
•	 Urinary biomarkers: NGAL, α1-microglobulin, KIM-1, H-FABP, MCP-1 and 
creatinine (spot urine) 
•	 FGF23 (serum and spot urine) 
•	 Vitamin D, PTH, calcium and phosphate (serum) 
•	 GI symptom questionnaire 
•	 EuroQol questionnaire 
Every visit 
•	 Adverse events and concomitant therapy 
•	 Drug accountability 
•	 Physical examination and vital signs 
•	 Weight 
•	 Estimated GFR (MDRD) 
•	 Laboratory tests: hematology, biochemistry and lipid profile 
CT Scanning and 3-Dimensional Volumetry 
CT scans at baseline and week 24 will be performed on a multidetector CT scanner 
(Somatom Sensation 16 or 64; Siemens Medical Solution AG, Erlangen, Germany). All 
CT scans are blinded to patient identity and date of birth as well as date of scan. The 
effect of lanreotide will be evaluated by 3D total liver and kidney volume measurement 
of CT scan slices using Pinnacle3® version 8.0 g (Philips, Eindhoven, The Netherlands). 
Imaging protocol includes that CT scans have a slice thickness of 3 mm, and liver and 
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separate kidneys will be outlined manually every 9 mm. The software interpolates the 
intermediate slices and calculates the areas within the indicated circumference, and 
finally, total liver or kidney volume. The vessels and the ureter in the area of the renal 
hilum are excluded from manual volumetric marking. Unblinding of CT scans will be 
performed after all liver and kidney volumes are measured. 
Intermediate volume identification on CT images 
Intermediate volume will be assessed as described earlier.21 Briefly, the kidneys will be 
outlined manually on all acquired digital images using interactive image editing software 
(GIMP; GNU Image Manipulation Software, www.gimp.org). Subsequently, as an image 
enhancement step, anisotropic diffusion filtering will be used to smooth high-frequency 
noise. 21 Binary masks generated from the image outlines will be applied to the enhanced 
images, and image segmentation will be applied to the resulting kidney regions using 
a statistical approach known as Otsu’s thresholding.24 After the application of Otsu’s 
method with a number of classes equal to 4, each voxel in the volume will classified as 
fat, cyst, intermediate, or parenchyma. From the segmented images, cyst, intermediate, 
and parenchymal volumes will be computed by multiplying the voxel count of each 
class by voxel volume, as determined by the acquisition protocol.21 Validation of the 
segmentation procedure is described previously.21 
Study withdrawal 
Patients will be withdrawn from the study for any of the following reasons: withdrawal 
of informed consent, pregnancy, failure to adherence to protocol requirements, 
unacceptable toxicity, surgical intervention during the trial and if the investigators 
conclude that it is in the patient’s best interest for any reason. There will be no option of 
replacement into the study after withdrawal. 
Sample size considerations 
A previous trial suggested that 6-month treatment with lanreotide induced a 134 ml 
decrease in total liver volume in polycystic liver patients.8 For the purpose of this study 
we assumed that lanreotide is able to resort in a similar effect in patients with exclusively 
ADPKD. A sample size of 39 will achieve 80% power to detect a difference of 150.0 mL (SD 
325.0 ml) in liver volume (pre versus after treatment) using a two-sided α-level of 0.05. 
Taken into account a dropout rate of 10%, the sample size has to be 43 for the complete 
cohort. 
Statistical analysis 
All outcomes will be analyzed on an intention-to-treat basis. Parallel analyses conducted 
on per-protocol population will be performed. The volume of the liver will be determined 
as mentioned before. For primary and secondary endpoints, absolute and relative 
differences between baseline and end of treatment will be analyzed using a paired two-
sided t-test, or Wilcoxon ranked sum test where appropriate. All statistical analyses will 
be two-sided with a critical significance level of 5%. 
To evaluate which biomarkers predict treatment response to lanreotide, the association 
between each biomarker (NGAL, α1-microglobulin, KIM-1, H-FABP, MCP-1 and FGF23) 
and each of the primary and secondary outcomes will be examined by univariate linear 
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regression analyses. Predictors that are univariately associated with the outcome 
(p-value < 0.10) will be included in multivariate linear regression analyses. The model 
will be reduced by excluding predictors from the model with a p-value of > 0.05. In 
addition, the following variables will also be included in univariate models as predictors 
of favorable outcome as a secondary analysis: age, baseline liver volume, baseline kidney 
volume, kidney intermediate volume and estimated renal function (MDRD and cystatin 
C). All abnormal laboratory results will be listed and frequency tables will be compiled for 
Adverse Events classified according to the standard WHO-ART Body System Dictionary 
and preferred terms. 
Ethical considerations 
Ethical approval has been obtained from the local ethics committee of the Radboud 
University Nijmegen Medical Center. This study will be performed in accordance with the 
protocol, the guidelines of Good Clinical Practice/ICH, the principles of the Declaration 
of Helsinki 1964 as modified by the 52nd WMA General Assembly, Edinburgh, Scotland, 
October 2000 including two notes of clarification paragraph 29 and 30, and the local 
national laws governing the conduct of clinical research studies. All subjects have the 
right to withdraw from the study at any time during the trial. Safety of trial subjects is 
monitored by an independent data safety monitoring board (DMSB). 
Discussion 
Treatment with lanreotide may results in several identifiable benefits for ADPKD patients 
with polycystic liver disease. It may map the road to a causal therapy for patients with 
polycystic liver disease. Current surgical procedures carry the risk of considerable 
morbidity and not all patients are qualified for this approach. Alternative options are 
needed and our trial will establish whether and to which extent and in whom lanreotide 
treatment can reduce liver volume growth in ADPKD. 
The main strength of the RESOLVE trial is to determine whether lanreotide decreases 
liver volume in patients with ADPKD. Another group performed a post-hoc analysis of 
data from a randomized, cross-over study in 12 patients with ADPKD. 5 In this analysis, 
they evaluated the effect of octreotide in 12 ADPKD patients with polycystic livers and 
found a beneficial effect on liver volume.6 However, these findings must be taken with 
caution due to the small sample size and because carry over effects cannot be excluded 
given the cross-over design. This will be the first trial that is powered to detect a small but 
significant change in polycystic liver volume in ADPKD patients treated with lanreotide. 
Furthermore, although we predetermined renal volume and renal function as a 
secondary outcome, the inclusion of exclusively ADPKD patients allows us to evaluate an 
effect of lanreotide on kidney volume and function. Third, intermediate volume is tightly 
connected to the decline in GFR and might be useful as a marker for ADPKD progression.15 
In this trial, we will investigate whether lanreotide has a beneficial effect on intermediate 
volume. Fourth, it is still unknown which patient factors predict treatment response to 
somatostatin analogues. Urinary and serum biomarkers associated with ADPKD disease 
severity are assessed in the RESOLVE trial at baseline and at end of treatment.16, 17 We 
hope to correlate these markers to treatment response as this will allow us to give 
evidence based recommendations which ADPKD patients will benefit specifically from 
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treatment with lanreotide. Finally, this design provides an opportunity to study the safety 
of lanreotide in ADPKD patients with symptomatic polycystic liver disease. 
There are limitations that come with our study worth addressing. First, as we seek 
polycystic liver targeting, ADPKD patients with symptomatic polycystic livers and only 
mildly enlarged polycystic kidneys are not excluded from the RESOLVE trial. To properly 
evaluate the effect of lanreotide on polycystic kidney volume, we should have introduced 
a minimal threshold of total kidney volume. Second, we do not include a control arm in 
our trial, but rather sought comparison with values at baseline. This prevents us from 
direct comparison with untreated ADPKD patients. However, based on our observations 
and the data from placebo arms of other randomized clinical trials, it is possible to 
establish the natural course of symptomatic polycystic liver disease. In our original trial, 
an increase of 1.6% in liver volume was observed after 6 months, while in another trial 
liver volume increased with 0.9% after 12 months.7, 8 Both these trials included a mixture 
of APDKD and PCLD patients. Liver volume increased with 1.2% during 6 months in a 
third trial that included exclusively ADPKD patients.6 As the natural growth pattern of 
polycystic liver disease does not seem to differ between ADPKD and PCLD, we may use 
the data from these placebo arms to evaluate if lanreotide affects the growth of polycystic 
liver volume. In addition, the lack of a control group guarantees that a possible effective 
therapy is not withheld from symptomatic PLD patients included in the trial, and that the 
results will be directly applicable to ADPKD patients in the daily practice. 
Despite these limitations, our study will add valuable information to the literature of 
medical treatment of polycystic liver disease. 
In conclusion, by designing the RESOLVE trial, we anticipate that lanreotide is an effective 
therapeutic option for ADPKD patients with symptomatic polycystic livers, and we hope 
to identify patient related factors that predict treatment response. 
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Abstract
Background & Aim
Several trials have demonstrated that somatostatin analogues decrease liver volume 
in mixed populations of patients with autosomal dominant polycystic kidney disease 
(ADPKD) and isolated polycystic liver disease. Chronic renal dysfunction in ADPKD may 
affect treatment efficacy of lanreotide and possibly enhances risk for adverse events. 
The aim of this open-label clinical trial (RESOLVE trial) was to assess efficacy of 6 months 
lanreotide treatment 120 mg subcutaneously every 4 weeks in ADPKD patients with 
symptomatic polycystic liver disease.
Methods
Primary outcome was change in liver volume after 6 months, secondary outcomes were 
changes in kidney volume, eGFR, symptom relief and health-related quality of life (Euro-
Qol5D). We excluded patients with an estimated glomerular filtration rate (eGFR) < 30 
ml/min/1.73m2. We used the Wilcoxon signed-rank test or paired two-sided t-test to 
analyze within-group differences.   
Results
We included 43 ADPKD patients with polycystic liver disease (84% female, median age 50 
years, mean eGFR 63 ml/min/1.73m2). Median liver volume decreased from 4,859 ml to 
4,595 ml (-3.1%;p<0.001), and median kidney volume decreased from 1,023 ml to 1,012 
ml (-1.7%;p=0.006). eGFR declined 3.5% after the first injection, remained stable up to 
study end, to decline again after lanreotide withdrawal. Lanreotide significantly relieved 
postprandial fullness, shortness of breath and abdominal distension. Three participants 
had a suspected episode of hepatic or renal cyst infection during the study.
Conclusion
Lanreotide reduced polycystic liver and kidney volumes and decreases symptoms in 
ADPKD patients. Moreover, eGFR decreased acutely after starting lanreotide, stabilized 
thereafter and declined again after withdrawal.
47
Lanreotide in ADPKD
3b
Background
A subset of patients with autosomal dominant polycystic kidney disease (ADPKD) develops 
significant hepatomegaly due to polycystic liver disease.1-4 Subsequently mechanical 
complaints may arise in this specific subgroup of patients and compromise quality of 
life.5, 6 Although surgical therapies may be successful in reducing liver volume in selected 
patients, they are only partial effective, cause significant morbidity and mortality, and 
most importantly, are unable to change the natural course of the disease.7-9 
Somatostatin analogues, including lanreotide and octreotide, are thought to decrease 
polycystic liver volume through their ability to reduce cAMP.8, 10 In the last few years, 
several trials have demonstrated the liver and kidney volume reducing effects of 
lanreotide and octreotide in patients with isolated polycystic liver disease and ADPKD.11-15 
Moreover, a recent meta-analysis showed that 6-12 months of somatostatin analogue 
therapy decreased polycystic liver volume with 5.3% in polycystic liver disease patients 
when compared to placebo.16 These observations clearly support the thesis that growth 
of polycystic liver and kidneys can be suppressed by somatostatin analogues. 
However, these studies included a diverse population of patients with or without cystic 
kidneys. It is possible that chronic renal dysfunction in ADPKD affects treatment efficacy of 
lanreotide and possibly enhance risk for adverse events. In addition, the aforementioned 
trials also included patients without symptoms related to their enlarged liver, which 
complicates assessment of treatment response.
To eliminate these possible confounding factors, we have designed and initiated an 
observational trial to examine the efficacy of lanreotide in reducing liver and kidney 
volumes in ADPKD patients with symptomatic polycystic liver disease. We also determined 
the effect of lanreotide on renal function, gastrointestinal symptoms and health-related 
quality of life.
Methods/design
A detailed protocol of the study procedures has been described elsewhere. A brief 
caption follows below.17
Study population
Symptomatic ADPKD patients with polycystic livers (Gigot type II or III) were eligible 
for study participation.18 Inclusion criteria were age between 18 and 70 years and 
an estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73m2 using the 
abbreviated Modification of Diet in Renal Disease Study equation (MDRD).19 Symptomatic 
patients were defined as ECOG-Performance scale ≥ 1 and three or more of the following 
symptoms: abdominal pain/distension/fullness, dyspnoea, early satiety, back pain, 
nausea/vomiting, anorexia, weight loss and jaundice. ADPKD diagnosis was based upon 
the modified Ravine criteria.20 Major exclusion criteria were renal transplantation; oral 
contraceptives or estrogen substitution; surgical intervention targeted at liver or kidneys 
or somatostatin analogue treatment within 3 months before baseline.
Study design and setting
This observational trial was performed at the Radboudumc, Nijmegen, the Netherlands 
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from May 2011 until April 2013. All patients received long-acting lanreotide (Somatuline®, 
Ipsen, Boulogne Billancourt, France) 120 mg subcutaneously every 4 weeks for a total of 24 
weeks and received a CT at baseline and end of treatment. Lanreotide was administered
At patient’s homes by independent nurses.
Outcome measures
Primary outcome of this trial was change in total liver volume (TLV) after 24 weeks of 
treatment with lanreotide compared to baseline, as determined by CT volumetry. 
Secondary outcomes were change in total kidney volume (TKV), as determined by CT 
volumetry; change in eGFR; change in creatinine clearance, as determined by 24-hour 
urine collection; change in gastrointestinal symptoms, as assessed by the gastrointestinal 
(GI) symptoms questionnaire; and change in health-related quality of life, as assessed 
with Euro-QoL (EQ-5D) questionnaire, all measured at the same time points. eGFR was 
assessed by using creatinine-based estimation equations, the 4-variable MDRD formula19 
and chronic kidney disease epidemiology collaboration formula (CKD-EPI).
The GI symptoms questionnaire assesses type and severity of 11 symptoms on a 
7-point adjectival scale, and uses a visual analogue score (VAS) to measure abdominal 
pain.21 The EQ-5D consists of five dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) and a health state assessment (EQ-VAS). Each of 
the five dimensions can take one of three responses (no/some/severe limitations).22 We 
dichotomized GI and EQ-5D questionnaire scores for absence or presence of symptoms/
limitations. Finally, frequency and severity of all reported adverse events were recorded 
at every visit to evaluate the safety and tolerability of lanreotide therapy. 
CT Scanning and 3-Dimensional Volumetry
CT scans at baseline and week 24 were performed with a multidetector CT scanner (Toshiba 
Aquilion-one, Toshiba Medical Systems, Zoetermeer, The Netherlands). All CT scans were 
blinded to patient identity, date of birth and date of scan. The effect of lanreotide was 
evaluated by 3D total liver and kidney volume measurement of CT scan slices using 
Pinnacle3® version 8.0h (Philips, Eindhoven, The Netherlands).17 Unblinding of CT scans 
was performed after all liver and kidney volumes were measured by two independent 
researchers (TG&JH). To warrant limited measurement bias, the interobserver variability 
was assessed in a set of 8 CT scans using a Bland-Altman plot. The Bland-Altman plot 
showed a mean difference of -0.4±0.6% between the two researchers that performed CT 
volumetry, indicating excellent agreement.
Statistical analysis
Based on a previous trial, we expected that 6 months of lanreotide treatment induced a 
mean difference of 150 ml (standard deviation 325 ml) in TLV in ADPKD patients.14 Based 
on these assumptions a sample size of 39 will achieve 80% power to detect this expected 
difference in liver volume (pre versus after treatment) using a two-sided α-level of 0.05. 
Taken a dropout rate of 10% into account the sample size for this trial was 43.  
All primary and secondary outcomes were calculated according to the intention-to-treat 
principle. Patients who dropped out the trial before end of treatment (24 weeks after 
baseline) received a preliminary end-of-treatment CT scan for the benefit of the intention-
to-treat analysis. In addition, for patients without an outcome at end-of-treatment, we 
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used the ‘last observation carried forward’ method to impute missing data. We calculated 
means±standard deviations or medians with interquartile ranges (IQR) for normally or 
non-normally distributed data respectively. As liver and kidney volumes have a skewed 
distribution, we used the Wilcoxon signed-rank test to analyze within-group differences. 
Within-group differences were analyzed using the paired two-sided t-test for the other 
secondary endpoints. Associations between TLV and TKV changes were evaluated by 
Spearman’s correlation test. McNemar’s test was used to compare paired dichotomized 
outcomes. All statistical analyses were two-sided with a significance level of 5% and were 
performed with SPSS statistical software package version 20.0 (SPSS Inc., Chicago, IL). 
Ethical considerations
Ethical approval was obtained from the local institutional review board (IRB), the 
committee human research region Arnhem-Nijmegen (CMO Arnhem-Nijmegen). This 
study was performed in accordance with the protocol, guidelines of Good Clinical 
Practice/ICH and the principles of the Declaration of Helsinki 1975. Safety of trial subjects 
was monitored by an independent data safety monitoring board. We obtained patient 
consent from every included participant. 
Results
Fifty-one ADPKD patients were assessed for eligibility to participate in the trial (Figure1). 
Reasons for exclusion were eGFR < 30 ml/min/1.73m2 (n=4), an autosomal dominant 
polycystic liver disease diagnosis (n=3) or absence of polycystic liver disease on CT (n=1). 
Finally, we assigned 43 ADPKD patients with polycystic liver disease (mean eGFR 63 ml/
min/1.73m2) to treatment with lanreotide. Baseline characteristics are shown in Table1. 
One patient underwent double-J ureteral stent placing of the right kidney during the 
trial, which beneficially affected renal outcomes at end of treatment. Therefore, we used 
this patient’s baseline data to impute renal data at end of therapy, for the benefit of 
the intention-to-treat analysis. A total of 42 patients (98%) completed the full 24-week 
treatment period, as one patient withdrew consent 16 weeks after baseline due to 
decreasing eGFR. This patient received a premature end-of-treatment CT scan.
 
Liver volume
Median TLV decreased from 4,859 mL (IQR 3,110-7,822 mL) at baseline to 4,595 mL (IQR 
3,172-7,910 mL) in the 43 ADPKD patients treated with lanreotide, which is an average 
reduction of -3.1±4.6% (Figure2A). The difference in TLV was statistically significant (-187 
mL;p<0.001) using the Wilcoxon signed-rank test (supplementary Figure1). The majority 
of patients (84%) responded with a decrease in liver volume.
Kidney volume 
In the 43 lanreotide-treated patients, median TKV declined from 1,023 mL (IQR 619-
2,365 mL) to 1,012 mL (IQR 597-2,378 mL), with an average decrease of -17 mL (p=0.006). 
This corresponds with a mean decrease of -1.7±3.4% (Figure2B; supplementary Figure1). 
Two-third of patients (67%) showed a reduction in total kidney volume.
Changes in TLV and TKV were weakly correlated (r=0.37;p=0.01). 
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Liver volume analysis
43 patiens analysed in intention-to-treat analysis
-1 patient with preliminary end-of-treatment CT scan
43 patiens included in study and 
assigned to lanreotide
51 patients assessed for eligibility
Exclusion criteria:
eGFR <30 ml/min/1.73m2 (n=4)
No diagnosis of ADPKD (n=3)
No polycystic liver (n=1)
Kidney volume and renal function analyses
43 patiens analysed in intention-to-treat analysis
-1 patient with preliminary end-of-treatment CT scan
-1 patient with imputed renal endpoints
Figure 1: Trial profile. eGFR, 
estimated glomerular filtration 
rate; ADPKD, autosomal 
dominant polycystic kidney 
disease.
Age  (y) 51±9 
Gender  
   Female 
   Male 
36 (84) 
7 (16) 
Liver volume (ml) 4859 (3110 – 7822) 
Kidney volume (ml) 
eGFR (ml/min/1.73m2) 
Creatinine clearance (ml/min)a 
Weight (kg) 
1023 (619 – 2365) 
63±17 
79±24 
74 (67 – 83) 
BMI (kg/m2) 26 (23 – 28) 
SBP (mmHg) 129 (120 -141) 
DBP (mmHg) 82 (72 – 88) 
Current blood pressure lowering medication  
Angiotensin-converting-enzyme inhibitor, 
angiotensin-receptor blocker, or both 
History of renal cyst infection 
History of hepatic cyst infection
33 (77) 
 
30 (70) 
3 (7) 
4 (9) 
Renal function
Mean eGFR (MDRD equation) decreased from 63±17 to 60±17 ml/min/1.73m2 after 
24 weeks of lanreotide (-4.0%;p=0.01;Figure3). This finding was confirmed by changes 
observed in 24-hours creatinine clearance, which decreased from 79±24 to 74±23 ml/
min (-5.6%;p=0.002). Figure 3 illustrated that eGFR primarily declined between baseline 
and 4 weeks after start of therapy (-3.5%;p=0.004) and remained stable thereafter. 
Table 1: Baseline demographic, clinical, and laboratory characteristics of 43 included patients 
Data are reported as median (interquartile range), mean ± standard deviation or absolute numbers (%). eGFR 
is estimated by the abbreviated MDRD equation. eGFR, estimated glomerular filtration rate; BMI, Body Mass 
index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure. aDetermined by 24-h urine collection.
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Furthermore, this initial decline in eGFR was associated with a small, although not 
significant, increase in mean arterial pressure (MAP). We repeated these analyses using 
the CKD-EPI equation instead of the MDRD equation, as the CKD-EPI equation might 
estimate renal function more accurately than the MDRD equation. Both analyses gave 
similar results.
We measured the eGFR in 40 patients after a median follow-up duration of 4.5 months 
(IQR 3-7 months) after stopping lanreotide. Mean eGFR significantly decreased from 
60±17 ml/min/1.73m2 to 57±17 ml/min/1.73m2 (-3.4%;p = 0.03; Figure 4). Decline in 
Figure 2: Individual changes in total liver and kidney volumes 
during therapy. Total liver (A) and kidney (B) volumes in each 
individual patient (n = 43) at baseline (0 weeks) and after 24 
weeks of lanreotide treatment.
eGFR on lanreotide therapy and after stopping was similar, with a reduction of 0.6%/
month and 0.8%/month respectively. The decline in eGFR between 4 and 24 weeks of 
treatment was numerically smaller than after stopping lanreotide (0.0%/month versus 
-0.8%/month), although this difference was not statistically significant (p = 0.23).
Blood pressure lowering drugs
We started blood pressure lowering drugs in five patients after baseline (Angiotensin-
converting-enzyme inhibitor (n=3), diuretics (n=2)), and altered dose of diuretics in two 
other patients. Since changes in blood pressure affect glomerular filtration, the analyses 
were also performed after excluding these 7 patients. Again, eGFR initially decreased 
with -3.6% after 4 weeks of treatment (p=0.008), and was stable between 4 and 24 weeks 
Figure 3: Changes in eGFR and mean 
arterial pressure during therapy. eGFR, 
calculated with the MDRD equation, 
and mean arterial pressure (MAP) at 
baseline and after 4, 12 and 24 weeks 
of lanreotide therapy in 43 ADPKD 
patients evaluated for renal outcomes. 
Blood pressure data was available for 
42 ADPKD patients. eGFR, estimated 
glomerular filtration rate; MAP, mean 
arterial pressure. Data is mean with 
standard error. NOTE: both Y-axis do 
not intersect at 0 with the X-axis.
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of therapy (supplementary Figure2). MAP also increased during these first 4 weeks of 
therapy, although not significantly (+2.0%;p=0.4). By contrast, the initial decrease in eGFR 
in the 7 patients who started or changed their blood pressure medication continued 
after 4 weeks (-10.0%;p=0.008; supplementary Figure3). In parallel, MAP significantly 
decreased during the same observation period (-8.8%;p=0.03).  
Figure 4: Changes in eGFR during and after 
stopping lanreotide therapy. eGFR, calculated 
with the MDRD equation, at baseline, 4, 
12 and 24 weeks on lanreotide and after 
a median of 18 weeks off lanreotide in 40 
ADPKD patients evaluated for renal outcomes 
after stopping lanreotide. eGFR, estimated 
glomerular filtration rate. Data is mean with 
standard error. NOTE: the Y-axis does not 
intersect at 0 with the X-axis.
Gastrointestinal symptoms and Health-related quality of life
We assessed GI symptoms through a specified GI questionnaire. Lanreotide therapy 
significantly lowered early satiety from 86% to 61% (p=0.003), abdominal distension from 
74% to 35% (p<0.001) and shortness of breath from 72% to 51% (p=0.01;Supplementary 
Table1). 
Next, we determined the health status of participating patients through the EQ-5D 
questionnaire. Treatment with lanreotide had no effect on any of the five dimensions of 
the EQ-5D or on health state (Supplementary Table2). 
Safety endpoints
Adverse events
Four patients receiving lanreotide were hospitalized during the trial. One female patient 
had urinary tract infection at baseline and developed pyelonephritis with right kidney 
pyelum obstruction three days after the first lanreotide injection. She was adequately 
treated with intravenous antibiotics and a double-J ureteral stent. Two other female 
patients, both with a history of cyst infections, were hospitalized eight and ten weeks after 
start of lanreotide because of suspicion of liver or kidney cyst infection, respectively. Both 
patients recovered fully after a course of antibiotics. Finally, one patient was hospitalized 
with a hepatic cyst bleeding eight weeks after baseline, which was adequately treated 
with analgesics (Supplementary Table3). 
No patient withdrew because of side effects of lanreotide, needed dose reduction or missed 
a dose. Most common side-effects were diarrhea, loose stools and abdominal cramps 
which occurred mainly after the first injection and were self-limiting (Supplementary 
Table3). Seven patients developed mild steatorrhea during the trial, although not 
confirmed by fecal fat excretion, which was successfully treated with pancreatic enzymes 
in three participants. No patient developed symptomatic cholelithiasis. One patient with 
a history of cyst infection developed mild fever, abdominal pain, coughing and malaise 
20 weeks after start of lanreotide, and was successfully treated with oral antibiotics for 
suspicion of hepatic cyst infection at our outpatient clinic.  
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Laboratory outcomes
Laboratory results showed no clinically relevant or statistically significant changes 
throughout the treatment period, except for blood glucose levels which moderately 
but significantly increased from 93.7 to 100.9 mg/dL (p<0.001;Supplementary Table4). 
Elevated glucose levels returned to normal after cessation of lanreotide in all patients. 
One patient was treated for hyperglycemia which occurred after concomitant use of 
corticosteroids. Plasma glucose levels returned to normal after ending corticosteroid 
treatment, and blood glucose lowering therapy was stopped.
Discussion 
Our key finding is that 24 weeks of lanreotide therapy significantly reduces liver and kidney 
volumes in ADPKD patients and that treatment was associated with less postprandial fullness, 
shortness of breath and abdominal distension. eGFR decreases in the first 4 weeks after start, 
with a subsequent stabilization on therapy but a further decline after stopping lanreotide. 
The observed decrease of 187 ml (-3.1%) in TLV is consistent with previous results. One 
trial evaluated 6 months of 120 mg lanreotide in 54 patients with polycystic liver disease 
and found a decrease of -2.9% in TLV.14 A second trial saw that a 6-month course of long-
acting octreotide (40 mg) reduced TLV by -4.5% in 12 ADPKD patients, although these 
patients had mild polycystic liver disease (mean liver volume 1608 ml).11 How do these 
values compare to the natural course of TLV? A recent pooled analysis that included 
the individual data of all placebo arms from RCTs found that TLV remained stable in 
ADPKD over the course of 6-12 months.16 Our results suggest that lanreotide changes 
the natural course of TLV progression in ADPKD, and that this effect seems unaffected by 
mild to moderate renal dysfunction (>30 ml/min/1.73m2). Whether lanreotide therapy is 
effective in patients with end-stage renal disease remains to be investigated.
Growth of renal volume is much more unrelenting than that of the liver. It is estimated 
that polycystic kidneys grow by 5.3% annually.23 This contrasts with results from this 
trial where lanreotide decreases TKV by 17 ml (-1.7%). These results parallels that of a 
subgroup analysis from a recent lanreotide trial.14 By contrast, a cross-over study that 
evaluated 6 months of octreotide in 12 ADPKD patients found that TKV increased while 
on therapy, although less than with placebo (+71 ml versus +162 ml).13 Similar findings 
were observed in the ALADIN trial, which showed an increase of 46 ml in TKV after 1 
year of octreotide therapy in ADPKD patients.15 This discrepancy could be explained by 
differences in efficacy between lanreotide and octreotide. Another explanation is that 
patients included in the octreotide studies had more progressive disease compared to 
our patients, which is supported by the higher baseline TKV in the cross-over study (2551 
ml) and ALADIN (1557 ml) trial compared to the 1023 ml in this trial. 
We showed that eGFR significantly decreased after 24 weeks of lanreotide. Of note, there 
was an initial reduction in eGFR in the first four weeks after baseline and a stabilization 
thereafter. Several mechanisms may contribute to this initial decline. First, starting 
antihypertensives in a subset of patients may have contributed to the decline in renal 
function. However, excluding these patients gave similar results. Second, the decrease in 
eGFR in the first weeks following the first lanreotide injection suggest causal inference. 
Indeed, somatostatin acutely decreases GFR in healthy subjects and patients with liver 
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cirrhosis, probably by renal vasoconstriction.24-26 The (small) increase in MAP after 4 
weeks of treatment also suggests a vasocontrictive effect. It is possible that this acute 
effect is maintained, causing the decrease in eGFR. Finally, the progression of chronic 
renal dysfunction in ADPKD decreases eGFR, which adds to a possible vasoconstricting 
effect of the drug. Our results show that the administration of lanreotide at a dose of 120 
mg may cause a significant and irreversible reduction in eGFR, and physicians should be 
aware of this when starting treatment in ADPKD patients.
We found that eGFR stabilizes beyond 4 weeks of therapy and that eGFR significantly 
decreases again after stopping lanreotide. This may suggest a renoprotective effect of 
lanreotide, although a rebound effect or sudden onset of progression of renal disease 
cannot be excluded. Our hypothesis is supported by the findings from the ALADIN trial, 
which compared 3 years of long-acting octreotide to placebo in 79 ADPKD patients with 
preserved or mildly impaired renal function.15 Both groups showed decreases in measured 
GFR after 1 year of treatment. Beyond that year, renal function trajectories began to 
diverge, showing a declining trend in placebo but not for octreotide. These findings 
suggest that somatostatin analogues may stabilize renal function in ADPKD, although this 
must be confirmed by future trials that are controlled and adequately powered. Indeed, 
the DIPAK trial (NCT01616927) is currently evaluating effect of 3 years of lanreotide in 
300 ADPKD patients on renal function and includes liver and kidney volume as secondary 
outcomes.27
Lanreotide therapy ameliorated postprandial fullness, shortness of breath and abdominal 
distension in these patients, but this did not translate in a beneficial effect on health-
related quality of life in the short-term. As ADPKD is a chronic disorder, longer follow-up 
periods and more sensitive questionnaires are probably necessary to properly investigate 
effects of somatostatin analogues on symptoms and health-related quality of life, 
preferably in a blinded setting. 
Consistent with previous studies, diarrhoea and abdominal cramps were most common 
side-effects of lanreotide therapy.14, 28 All hyperglycaemias were reversible and there was 
no symptomatic cholelithiasis in our study. However, a previous study demonstrated 
increased prevalence of gallstones in patients with acromegaly who were treated up 
to 18 years, indicating the potential risks of prolonging therapy.29 Three patients were 
suspected of hepatic or renal cyst infection during our study. Even though diagnosis was 
not confirmed by 18FDG-PET/CT or cyst aspiration and a comparative control arm was 
lacking, this number seems high as the incidence of cyst infection in ADPKD is estimated 
at one per 100 patients per year.30 However, all three patients had an history of cyst 
infections, which may have increased the risk for new episodes of cyst infections. At any 
rate, renal dysfunction did not seem to increase side-effects in our trial patients when 
compared to previous studies, although this must be confirmed in the DIPAK1 trial.   
In our opinion, ADPKD patients with highly symptomatic polycystic liver disease ineligible 
for surgical therapies are good candidates for lanreotide therapy. Our results only apply 
for a treatment period of 6 months. However, two extension trials showed that prolonging 
somatostatin analogue therapy resulted in maintenance of the effect up to 2 years in 
mixed populations of patients with polycystic liver disease.28, 31 Discontinuation resulted 
in immediate recurrence of liver growth, indicating that continuous treatment will be 
necessary to maintain the beneficial effect. However, given the potential risks for long-
term treatment, including diabetes and symptomatic cholelithiasis, the use of lanreotide 
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in ADPKD should be reserved for centres who are familiar with guidelines of prescribing 
these drugs and have the facilities to perform liver volumetry.
The main strength of this trial is that it showed a clinically relevant decrease in polycystic 
liver volume in symptomatic ADPKD patients treated with lanreotide. The choice for 
an observational design guaranteed that a possible effective therapy was not withheld 
from these symptomatic patients. Although this design precludes direct comparison with 
untreated ADPKD patients, it increases external validity of our findings. As such they are 
directly applicable to clinical practice in real life. 
There are several limitations to our study worth addressing. First, all included ADPKD 
patients had a symptomatic polycystic liver, which makes extrapolation of findings to the 
general ADPKD population difficult. We had a low number of male patients in our study, 
which reflects the gender imbalance observed in polycystic liver disease. It is unknown 
whether these results also apply to men with polycystic liver disease. Second, we used 
prediction formulas to estimate GFR, which may be less reliable than measured GFR. 
Finally, as we seek polycystic liver targeting, ADPKD patients with only mildly enlarged 
polycystic kidneys and preserved renal function were not excluded. It is therefore possible 
that a proportion of patients has PKD2, which has better prognosis that PKD1.32 Larger 
controlled trials, including an upper limit of renal function and a longer follow-up period, 
are needed to determine to properly evaluate the renoprotective effects of lanreotide in 
ADPKD. 
In conclusion, lanreotide reduced polycystic liver and kidney volumes and decreased 
gastrointestinal symptoms in ADPKD patients. Furthermore, eGFR acutely decreased in 
these patients, but stabilized after continuation of lanreotide therapy. 
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Supplementary Figure 1: Percent changes in total 
liver and kidney volumes. Percent change in total 
liver volume (A) and total kidney volume (B) from 
baseline after 24 weeks of lanreotide therapy. Data 
is mean ± standard deviation. 
Supplementary Figure 2: Changes in eGFR and mean 
arterial pressure during therapy in patients without 
changes in antihypertensives. eGFR, calculated 
with the MDRD equation, and mean arterial 
pressure (MAP) at baseline and after 4, 12 and 24 
weeks of lanreotide therapy in 36 ADPKD patients 
evaluated for renal outcomes without changes in 
antihypertensives. Blood pressure data was available 
for 35 ADPKD patients. eGFR, estimated glomerular 
filtration rate; MAP, mean arterial pressure. Data is 
mean with standard error. NOTE: both Y-axis do not 
intersect at 0 with the X-axis.
Supplementary Figure 3: Changes in eGFR and mean 
arterial pressure during therapy in patients with 
changes in antihypertensives.eGFR, calculated with 
the MDRD equation, and mean arterial pressure 
(MAP) at baseline and after 4, 12 and 24 weeks of 
lanreotide therapy in 7 ADPKD patients evaluated for 
renal outcomes with changes in antihypertensives. 
Blood pressure data was available for all 7 patients. 
eGFR, estimated glomerular filtration rate; MAP, 
mean arterial pressure. Data is mean with standard 
error. NOTE: both Y-axis do not intersect at 0 with 
the X-axis.
Supplementary files
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 Lanreotide 
 T0 n/N (%)a T24 n/N (%)a 
Abdominal pain 
  In general 
  Postprandial 
  Fasting 
  Unrelated to defecation 
 
16/43 (37%) 
11/40 (28%) 
8/43 (19%) 
7/43 (16%) 
 
14/43 (33%) 
11/40 (28%) 
4/43 (9%) 
6/43 (14%) 
Epigastric  
   In general 
   During daytime 
   At night/asleep 
 
27/43 (63%) 
23/43 (54%) 
20/43 (47%) 
 
19/43 (44%) 
17/43 (40%) 
12/43 (28%) 
Heartburn 
Regurgitation 
Nausea 
Vomiting 
10/43 (23%) 
10/43 (23%) 
10/43 (23%) 
4/43 (9%) 
4/43 (9%) 
5/43 (12%) 
12/43 (28%) 
2/43 (5%) 
Loss of appetite 
Early satiety 
Shortness of breath 
14/43 (33%) 
37/43 (86%) 
31/43 (72%) 
16/43 (37%) 
26/43 (61%)* 
22/43 (51%)** 
Abdominal distension 
Involuntary weight loss 
VAS scoreb 
32/43 (74%) 
3/43 (7%) 
22 (7 to 51) 
15/43 (35%)*** 
6/43 (14%) 
20 (8 to 31) 
 Lanreotide 
 T0 n/N (%)a T24 n/N (%)a 
Mobility 
Self-care 
10/43 (23%) 
3/43 (7%) 
8/43 (19%) 
4/43 (9%) 
Usual activities 25/43 (58%) 22/43 (51%) 
Pain/discomfort 26/43 (61%) 28/43 (65%) 
Anxiety/depression 10/43 (23%) 9/43 (21%) 
Health state (EQ-VAS)b 70 (65 to 80) 71 (68 to 80) 
Supplementary Table 2: Results of the EuroQol-5D questionnaire
 Supplementary Table 1: Results of the gastrointestinal symptoms questionnaire  
* Compared to T0 (p =  0.003). ** Compared to T0 (p = 0.01). *** Compared 
to T0 (p< 0.001). Abdominal symptom severity ≥ 2 on a 7-point adjectival scale 
ranging from 0 to 6. VAS, visual analogue scale; scored on a range of 0-100 (0, 
no pain; 100, worst pain). aDenominators depend on the number of patients 
who provided an answer for a specific question in the questionnaire. bData are 
median (interquartile range). 
EQ-5D severity ≥ 2 on a 3-point scale (1 = no limitations, 2 = some limitations, 3 = severe limitations). EQ-
VAS, EuroQol visual analogue scale; scored on a range of 0-100 (0, worst imaginable health state; 100, best 
imaginable health state). a Denominators depend on the number of patients who provided an answer for a 
specific question in the questionnaire. b Data are median (interquartile range).
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Adverse event
 
 Lanreotide n/N (%)a 
Diarrhea/Loose stools 35/43 (81%) 
Abdominal cramps 34/43 (79%) 
Nodule at injection site 17/43 (40%) 
Nausea  13/43 (30%) 
Flatulence, bloating and gas  8/43 (19%) 
Steatorrhea 7/43 (16%) 
Constipation 
Suspected cyst infection (liver/kidney)b 
Haemorrhagic liver cystc 
Pyelonephritis with right kidney pyelum obstructionc
6/43 (14%) 
3/43 (7%) 
1/43 (2%) 
1/43 (2%) 
                                                                              T0                           T24 
Sodium (mmol/L) 139.1 ± 1.9 139.4 ± 1.5 
Potassium (mmol/L) 3.9 ± 0.3 3.9 ± 0.7 
Calcium (mg/dL) 9.6 ± 0.4 9.6 ± 0.4 
Phosphate (mmol/L) 1.0 ± 0.1 1.1 ± 0.2 
Bilirubin (mg/dL) 0.7 ± 0.3 0.6 ± 0.2 
Serum gamma-glutamyl transferase (U/L) 101 ± 92 107 ± 113 
Serum alkaline phosphatase (U/L) 97 ± 80 96 ± 70 
Serum albumin (g/L) 39.0 ± 3.4 40.1 ± 3.0 
Fasting plasma glucose (mg/dL) 93.6 ± 10.8 100.8 ± 10.8* 
Supplementary Table 3: Adverse events
Supplementary Table 4: Main laboratory parameters at start and end of lanreotide therapy
Data are reported as mean ± SD.* p < 0.001
a Denominator is total of patients in treatment arm. b Two patients were hospitalized. c Patient was hospitalized
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Abstract
Background & Aims
Clinical trials have shown that in patients with polycystic liver disease (PLD), short-term 
treatment with somatostatin analogues (SAs) reduces liver volumes by 4.5%−5.9%, 
compared with placebo. However, the effects of SA theYoung rapy vary among individuals. 
We collected data from individual patients with PLD to identify subgroups that benefit 
most from SA therapy.
Methods 
We analyzed data from 107 patients with PLD from 3 randomized placebo-controlled 
trials (67 received SAs, 52 received placebo). We used multiple linear regression analysis 
to determine the effects of SAs based on patients’ age, sex, baseline liver volume, and 
diagnosis (autosomal dominant polycystic liver disease or kidney disease). The primary 
outcome was change in liver volume after 6−12 months of treatment.
Results 
The effects of SA therapy did not differ significantly among patients with different 
diagnoses or baseline liver volumes; the overall difference in liver volume between 
groups receiving SAs therapy vs placebo was 5.3% (P<.001). Among subjects given 
placebo, young women (48 years old or younger) had the greatest increase in polycystic 
liver volume (4.8%; 95% confidence interval, 2.2%−7.4%), and mean liver volumes did 
not increase in older women and men.  Women 48 years old or younger had a greater 
response to therapy (a reduction in liver volume of 8.0%, compared with placebo; P<.001) 
than older women (a reduction in liver volume of 4.1%, compared with placebo; P=.022).
Conclusions 
Based on a pooled analysis of data from individual patients with PLD, treatment with 
somatostatin analogues is equally effective for patients with autosomal dominant 
polycystic kidney disease or polycystic liver disease; efficacy does not depend on size of 
the polycystic liver. Young female patients appear to have the greatest benefit from 6−12 
months of SA therapy, which might avert the progressive course of the disease in this 
specific group.
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Introduction 
Polycystic liver disease (PLD) is characterized by the progressive formation of multiple 
fluid-filled cysts throughout the liver, requiring liver transplantation in severe cases.1, 2 
Polycystic livers are the primary presentation in isolated autosomal dominant polycystic 
liver disease (PCLD), and can manifest as an extrarenal manifestation in autosomal 
dominant polycystic kidney disease (ADPKD).3-6 Current available treatment options are 
mainly surgical and aim at reducing liver volume to ameliorate mechanical symptoms.7-9 
Although these surgical procedures are effective in selected patients, the morbidity rate 
and their inability to alter the natural course of this disease highlights a clear need for 
new therapeutic options.
Somatostatin analogues (SAs), such as lanreotide, octreotide and pasireotide, are thought 
to decrease polycystic liver volume by curtailing cyclic adenosine monophosphate 
production in hepatic cysts.10, 11 After a randomized, placebo-controlled, clinical 
trial (RCT) showing that 6-month long-acting octreotide safely slowed renal volume 
expansion in ADPKD patients, 3 RCTs demonstrated that the efficacy of long-acting 
lanreotide or octreotide therapy reversed liver volume growth in PLD patients. 12-15 All 
trials demonstrated similar responses, with treatment effects of -4.5% to -5.9% in liver 
volumes when compared with placebo.16  
However, the treatment effect of SAs in these RCTs varied greatly amongst individual 
patients, ranging from gains of 300 mL to losses of 1500 mL in liver volume. In addition, 
results from 2 trials suggested those with larger polycystic livers had greater reductions in 
liver volume than those with smaller volumes.13, 14 Risk factors for liver cyst growth are age 
and female sex, which suggest that these may also impact treatment response to SAs.17, 
18 Finally, one trial reported similar effects of SA therapy in ADPKD and PCLD patients, but 
this trial lacked power to make final conclusions.14 Collectively, these findings suggest 
that treatment responsiveness can be increased in specific subgroups of PLD patients.   
Unfortunately, the relatively small number of patients and the specific patient 
characteristics has precluded any meaningful subgroup analyses within each of these 
individual RCT. Study level meta-analyses are adequate when estimating a single pooled 
treatment effect, but are limited in explaining heterogeneity, and do not relate effects 
of therapy to the single patient. To overcome these limitations and increase statistical 
power, we performed an individual patient data (IPD) pooled analysis using data from all 
available placebo-controlled randomized trials and investigated whether the efficacy of 
SAs is affected by patient factors. Therefore, the aim of the current IPD pooled analysis 
was to estimate the effect of SAs on polycystic liver volume in PLD subgroups based on 
underlying diagnosis, sex, age and liver size, to identify patients that respond best to 
therapy. 
66
Chapter 4
Materials and Methods
 
Literature search
We performed a systematic literature search in the following electronic databases: 
Pubmed (Medline), Cochrane Controlled Trials Register (CENTRAL), clinical trials.gov, and 
Web of Science from January 2000 until July 2012. The keywords ‘polycystic liver, ADPLD, 
PCLD or ADPKD’ and ‘somatostatin, SA, lanreotide, Somatuline®, octreotide, Sandostatine® 
or pasireotide’ and ‘placebo’ were combined. 
Study selection
We included all studies that were randomized, published as full articles or as an abstract, 
compared the effect of SAs to placebo in adult PCLD or ADPKD patients with a polycystic 
liver, and reported change in polycystic liver volume as the primary end point. Searches 
were limited to English, Dutch or German language. Only trials for which we obtained 
the actual data were included in the analysis. Authors were contacted for additional 
information in case the methodological quality of a trial was not adequately described 
in the original article. An additional search was performed using the references of all 
included trials to retrieve eligible studies possibly missed by our systematic literature 
search. 
Data abstraction
We sent an electronic form containing the data fields to be completed for individual 
patients to all principal investigators of the trials. Two authors (Tom J. G. Gevers and 
Joanna IntHout) who had not participated in any of the included RCTs pooled and analyzed 
all patient data. Subsequently, they checked databases for completeness and internal 
consistency and made corrections through correspondence with the investigators. The 
risk of bias was assessed using the Cochrane Collaboration’s tool for assessing risk of 
bias in randomized trials.19 The following domains were included for assessment of risk 
of bias: sequence generation, allocation concealment, blinding (masking) of participants, 
personnel and outcome assessors, description of the completeness of outcome data 
for each main outcome, assessment of selective reporting, and other sources of bias 
specific to the study. Authors were contacted for additional information in case the 
methodological quality of a trial was not adequately described in the original manuscript.
Outcomes
The primary outcome was change in liver volume as calculated by computed tomography 
(CT) or magnetic resonance imaging volumetry. The methods of volumetry are presented 
in detail elsewhere.12-14, 20, 21 As liver volumes were measured at different follow-up time 
points, we aggregated the data at 6 months and 12 months of follow-up. Secondary 
outcomes were safety, tolerability, and fasting plasma glucose levels, as glucose 
intolerance is a common side-effect of SA therapy. Patient subgroups included in the 
IPD pooled analysis were underlying diagnosis (ADPKD or PCLD), sex, age, and baseline 
liver volume. ADPKD was diagnosed in cases where >5 kidney cysts in either one or both 
kidneys were visible on CT; otherwise patients were diagnosed with PCLD. The age of the 
patient was assessed at baseline CT or magnetic resonance imaging.  
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Statistical analysis
The IPD pooled analysis was conducted according to the intention-to-treat principle as 
described in the original articles.12-14 As liver volumes have a skewed distribution, we 
first calculated the logarithms of liver volumes and then carried out the analyses. The 
treatment effect estimates were backwards transformed and the results were presented 
as mean percentage differences between SA and placebo, with 95% confidence intervals 
(CI). In the pooled analysis, we estimated the overall treatment effect of SAs on liver 
volume, using linear regression analysis with independent variables treatment group (SA 
or placebo); the logarithm of baseline liver volume; and patient characteristics of sex, 
age, and underlying diagnosis (APDKD/PCLD). We included the variable study as a fixed 
effect to take into account the heterogeneity among the different studies, which also 
included adjustment for differences in length of follow-up  (6 vs 12 months). Because 
one of the trials had a cross-over design, we also included the individual patient as a 
random factor.  For the primary objective, we evaluated the effect of SAs in subgroups 
by calculating interactions between treatment group (SA or placebo) and possible effect 
modifiers (diagnosis, sex, age, and logarithm of baseline liver volume). For this purpose, 
we added each interaction term (treatment group x potential effect modifier) separately 
to the main model. As multiple factors can affect growth of liver cysts, patients with 
more than one predisposing factor might have more severe disease and hence have 
more substantial benefits from SA therapy. Therefore, we subsequently investigated all 
possible interaction models, with varying combinations of interaction terms (all subsets 
of variables selection). To assess whether there was difference in fasting plasma glucose 
levels between treatment group (SA or placebo), we performed an analysis of covariance 
with post-treatment glucose levels as the dependent variable and baseline glucose levels, 
treatment group and study as independent variables. 
All statistical analyses were performed with SPSS statistical software package version 18.0 
(SPSS Inc., Chicago, IL) by Tom J. G. Gevers and Joanna IntHout and without the use of an 
external data coordinating center. All P values calculated were 2-tailed, and the level of 
significance was set at α= .05.
Role of Funding Source
This study was not supported by any company or grants. The costs were borne by the 
authors’ institutions.
 
Results
Our search strategy retrieved three RCTs that compared the effect of SA therapy on liver 
volume with placebo in PLD patients (Supplementary Figure 1). All 3 studies compared 
long-acting octreotide (Sandostatin LAR®, Novartis Pharma, Basel Switzerland) or 
lanreotide (Somatuline Autogel®, Ipsen, Boulogne Billancourt, France) with placebo in 
PLD patients, and each principal investigator agreed to provide individual patient data.12-14 
The first trial evaluated 6 months of lanreotide in 54 patients with PLD.14 The second trial 
investigated a 12 month regime of octreotide in 42 PLD patients.13 Both trials included a 
mixture of PCLD and ADPKD patients. The third study was a post-hoc analysis performed 
on a cross-over trial, in which 12 ADPKD patients received both SA and placebo for 6 
months.12 The general characteristics of the 3 trials included in the pooled analysis are 
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reported in Table 1. Concerning the methodological quality of the RCTs included in this 
trial, none of the included trials scored a high risk of bias on study or outcome level 
(Figure 1). In summary, the included trials were conducted in a double-blind fashion 
used a computer to generate the allocation sequence and reported adequate methods 
of treatment allocation (pharmacy controlled or central randomization). In addition, 
radiologists evaluating the primary outcome (liver volume) were blinded to treatment 
allocation and timing of the scan in all trials.
 
Baseline characteristics 
One female patient, who was randomly assigned to placebo, withdrew after 14 weeks 
because she was diagnosed with breast carcinoma and was excluded from analysis in the 
original study.14 Because this patient did not receive a CT-scan after withdrawal, she was 
also not included in our analysis. 
This resulted in a study population of 107 patients, including 12 patients of the cross-over 
trial that were measured twice. On average, women were 10 years younger compared 
with men (43.4 years vs 53.3 years at baseline), and the age of PCLD and ADPKD patients 
was similar (47.2 years vs 49.6 years). Table 2 shows the characteristics of the participants 
in each trial; more baseline characteristics are presented in the original articles.12-14 
Patients in the cross-over trial12 were more often male and had lower liver volumes 
First author 
 
Design Trial duration, 
months 
SA Population Inclusion criteria End points 
Van  Keimpema
200914
 
RCT (1:1) 6 Lanreotide 120 mg 
every 4 wks 
54 ADPKD/PCLD 
(27 drug, 27 
placebo)  
Older than 18 y; > 20 liver cysts TLVa, TKVa, 
SF36, safety 
Hogan, 
201013 
RCT (2:1) 12  Octreotide 40 mg 
every 4 wks 
42 ADPKD/PCLD 
(28 drug, 14 
placebo) 
Older than 18 y; liver volume > 
4000 ml or symptomatic liver 
disease and no candidate for 
surgery 
TLVb, TKVb, 
mGFR, SF36, 
safety 
Caroli, 
201012 
Randomized, 
cross-overc  
6  Octreotide 40 mg 
every 4 wks 
12 ADPKD (both 
drug and placebo) 
Older than 18 y; serum creatinine 
<265 µmol/L, but >106 µmol/L 
(men) or >88 µmol/L  (women) 
TLVa, TKVa, 
mGFR, safety 
than participants in the other 2 trials.13, 14 In addition, no PCLD patients were included 
in the cross-over trial.12 There were no significant differences in baseline characteristics 
between placebo and SA-treated patients (Table 2).
Pooled analysis
A total of 119 treatment periods, 67 in the group allocated to SA therapy and 52 in the 
placebo group, were included for analysis of change in liver volumes. No patient died 
or had a liver transplantation during the treatment periods. The majority of patients 
receiving an SA (82%) and only 44% of patients on placebo had a decrease of liver volume 
from baseline (Supplementary Figure 2). Reponses to SA therapy varied from increases 
of 9.7% to decreases of 17.3% in liver volume compared with baseline, indicating the 
large variability in treatment responses. After 6-12 months on placebo, the estimated 
Table 1: Design characteristics of the 3 RCTs  on SA vs placebo in patients with polycystic liver disease 
mGFR, measured glomerular filtration rate;  SF36, short form (36) Health Survey; TKV, total kidney volume; TLV, total liver volume. aMeasured by 
computerized tomography. bMeasured by Magnetic Resonance Imaging. cSecondary post-hoc analysis performed on data of this cross-over study.
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mean liver volume increased with 1.8% (95% CI: 0.0% to 3.8%) compared with baseline. 
In contrast, SA treatment resulted in a reduction of 3.6% (95% CI: -5.2% to -2.0%) 
(Supplementary Figure 3). Together, this resulted in an overall significant treatment effect 
of -5.3% in liver volume (95% CI -7.2% to -3.4%; P < .001) on SA therapy (Table 3). In 
order to assess whether we could aggregate data, we performed a sensitivity analysis 
comparing the effects of SA therapy from the 12-month trial 13 with effects observed in 
the 6-month trials. 12, 14. In both placebo and SA arms, we found no significant differences 
in change of liver volume between 6 and 12 months of follow-up (P = .49 and P = .87).
Diagnosis 
The effect of SA therapy was evaluated in PLD subgroups with PCLD and ADPKD as 
underlying diagnoses. On placebo, mean liver volume increased from baseline in PCLD 
patients, and it remained stable in ADPKD patients (3.8% vs 0.1%; p = .011) (Figure 2). 
In both subgroups, the significant treatment effects of SAs on liver volume were similar 
(-5.6% vs -5.2%; P = .87), indicating that diagnosis did not significantly affect treatment 
response (Table 3). 
Sex
Women on placebo had an average increase of 2.9% in liver volume from baseline, whereas 
livers did not grow noticeably in male patients on placebo (-0.1%) (Supplementary Figure 
4). SA therapy decreased liver volume to a similar extent in female and male patients 
(-3.6% vs -2.7%) compared with baseline. This resulted in a significant treatment effect 
of SAs in female patients (-6.4%; P < .001) when compared with placebo, and SA therapy 
was not significantly effective in men (-2.5%; P = .20), and a nonsignificant trend towards 
a better response was found in female PLD patients (P = .074) (Table 3).   
Figure 1: Risk of bias summary: review of authors’ 
judgments about each risk of bias item for each 
included study. -, low risk of bias; ?, unclear risk of 
bias; +, high risk of bias.
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van Keim
pem
a et al, 2009
14  
H
ogan et al, 2010
13 
Caroli et al, 2010
12 
Com
bined treatm
ent groups 
 
(n = 53) 
(n=42) 
(n=12) 
SA
 (n=55) a 
Placebo (n=40) a 
A
ge, y, m
edian (range) 
48 (32 – 67) 
47 (34 – 69) 
44 (33 – 57) 
47 (32 – 69) 
49 (36 – 67) 
Sex, n (%
) 
 
 
 
 
 
   Fem
ale 
   M
ale 
46 (87) 
7 (13) 
36 (86) 
6 (14) 
3 (25) 
9 (75)  
47 (85) 
8 (15) 
35 (88) 
5 (12) 
D
iagnosis, n (%
) 
 
 
 
 
 
   PCLD
 
   A
D
PKD
 
22 (42) 
31 (58) 
8  (19) 
34 (81) 
0 (0) 
12 (100) 
19 (35) 
39 (65) 
11 (27) 
29 (73) 
Liver volum
e, m
L, m
edian (range) 
4681 (1728 – 10,252) 
4452 (2234 – 13,148) 
1525 (1109 – 2788) 
4505 (1728 – 11,766) 
4707 (2004 – 13,148) 
W
eight, kg, m
edian (range) 
71 (52 – 95) 
72 (50 – 130) 
74 (58 – 100) 
71 (50 – 130) 
72 (53 – 93) 
BM
I, m
edian (range) 
25 (20 – 34) 
25 (18 – 41) 
25 (21 – 33) 
25 (18 – 41) 
25 (20 – 33) 
Serum
 bilirubin, µm
ol/L, m
edian (range) 
10 (9 – 32) 
9 (5 – 27) 
14 (5 – 26) 
9 (5 – 32) 
10 (5 – 27) 
Serum
 γ-glutam
yl transferase, U
/L, 
m
edian (range) 
73 (19 – 500) 
N
D
 
17 (2 – 51) 
85 (19 – 500) b 
71 (25 – 465) b 
Serum
 alkaline phosphatase, U
/L, 
m
edian (range) 
127 (36 – 697) 
83 (45 – 276) 
67 (36 – 89) 
91 (36 – 697) 
101 (56 – 298) 
Serum
 album
in, g/L, m
edian (range) 
4.3 (3.2 – 4.9) 
4.3 (3.9 – 4.8) 
4.2 (3.9 – 4.9) 
4.3 (3.2 – 4.9 ) 
4.3 (3.8 – 4.9) 
Serum
 creati
nine,  µm
ol/L, m
edian 
(range) 
71 (53 – 212) 
80 (53 – 230) 
150 (97 – 301) 
80 (53 – 230) 
71 (53 – 203) 
Serum
 glucose,  m
m
ol/L, m
edian (range) 
5.0 (4.0 – 7.5) 
5.1 (4.6 – 7.3) 
4.9 (4.1 – 6.4) 
5.0 (4.2 – 7.5) 
5.1 (4.0 – 7.3) 
Therapy, n (%
) 
 
 
 
 
 
   SA
 
   Placebo 
27 (51) 
26 (49) 
28 (67) 
14 (33) 
12
c (100) 
12
c (100) 
- - 
- - 
Table 2: Baseline characteristi
cs of included pati
ents w
ith polycysti
c liver disease in each trial and each treatm
ent group
BM
I, Body M
ass index; N
D
, not determ
ined. aPati
ents from
 the trial of Caroli et al 12 w
ere excluded because these pati
ents received both an SA
 and placebo. 
bIncluding data from
 the trial of Keim
pem
a et al 14 only. cPati
ents in the trial of Caroli et al 12 received both an SA
 and placebo. 
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Age
Age did not significantly influence the liver volume-reducing effects of SAs (P = .23) 
(table 3). Subsequently, we estimated the effect of SAs in age subgroups using the 
median of 48 years as a cut-off value. Younger patients showed more increase in liver 
volume on placebo than older patients (2.9% vs 0.5%) (Supplementary Figure 5). In both 
patients 48 years old and younger and patients older than 48 years old, the effect of SA 
therapy was significant when compared with placebo (-6.7% and -3.7%; P < .001 and 
P = .013).
Figure 2: Estimated percent changes (mean 
± 95% CI) in liver volumes in ADPKD and 
PCLD patients treated with somatostatin 
analogues or placebo for 6-12 months, 
calculated by multiple linear regression 
analysis. 
Baseline liver volume
We also evaluated the impact of polycystic liver size on treatment effect and observed 
that liver size did not affect mean response to SA therapy (P = .56) (Table 3). Next, we 
determined the effect of SA therapy in 2 subgroups of polycystic liver volumes, with low 
to medium volumes categorized as below the median and high volumes categorized as 
above the median. In both subgroups, patients had similar increases in liver volume on 
placebo (1.6% vs 2.4%) and showed significant treatment responses to SA therapy (-4.5% 
and -6.5%; P = .001 and P < .001). 
Patient group SA vs placebo, % (95% CI) P value Eﬀect modiﬁer (P value) 
All -5.3 (-7.2 to -3.4) <.001 NA 
Diagnosis  
   ADPKD 
   PCLD 
 
-5.2 (-7.5 to -3.0) 
-5.6 (-9.5 to -1.7) 
 
<.001 
.006 
No (0.87) 
Sex  
   Women 
   Men 
 
-6.4 (-8.5 to -4.2) 
-2.5 (-6.3 to 1.5) 
 
<.001 
.20 
Trend (0.074) 
Agea 
   48 y or younger 
   Older than 48 y 
 
-6.7 (-9.2 to -4.2) 
-3.7 (-6.5 to -0.8) 
 
<.001 
.013 
No (0.23) 
Baseline liver volumea 
  Low/Medium ( ≤ 4256 ml) 
  High ( > 4256 mla) 
 
-4.5 (-7.0 to -1.9) 
-6.5 (-9.4 to -3.5) 
 
.001 
<.001 
No (0.56) 
Table 3: Estimated mean percent changes in liver volumes after 6-12 months (SA compared with placebo), 
calculated by multiple linear regression analysis.  
NA, not applicable. aAge and baseline liver volume groups are defined by the median as the cut-off value
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Age-Sex subgroups
Post hoc, we performed an additional subgroup analysis, including patients with more 
than one predisposing factor, and included a subgroup for sex combined with age, using 
the median of 48 years as a cut-off value. On placebo, women 48 years old and younger 
had the largest growth in polycystic liver volume compared with baseline (4.8%), and liver 
volumes did not grow in women older than 48 years and in men (Figure 3). All subgroups 
had similar reductions in liver volume after SA therapy when compared with baseline. In 
both women 48 years old and younger and women older than 48 years, the treatment 
effects of SA on liver volume were significant (-8.0%; P < .001 and -4.1%; P = .022) when 
compared with placebo, with the best response in the younger women group (Table 4). In 
contrast, both men 48 years old and younger and men older than 48 years failed to show 
a significant treatment effect of SAs (-1.8%; P = .53 and -3.1%; P = .23). Overall, it seems 
that SA therapy is most beneficial for female PLD patients 48 years old and younger, 
although treatment interaction did not reach statistical significance (P = .084).   
Safety and tolerability 
No severe adverse events related to SA therapy were reported in the included RCTs. 
Although 3 patients receiving an SA were hospitalized during the 1-year study period of one 
trial, the causes were deemed to be unrelated to the study medication (ie, incarcerated 
abdominal hernia,  abdominal pain and fever responding to antibiotic treatment, and 
bacteremia associated with nephrolithiasis).13 In contrast, no patient on placebo was 
hospitalized. In addition, one patient had pre-existent asymptomatic nonobstructing 
gallstones, and another had gallbladder sludge. Both findings remained stable on SA 
therapy.13 Most common side effects related to SA therapy were gastrointestinal and 
included diarrhea/loose stools (51%); abdominal cramps (34%); and flatulence, bloating, 
and gas (30%) (Supplementary Table 1). Ten patients (15%) developed steatorrhea during 
SA therapy, which resolved in most patients after treatment with pancreatic enzymes. 
Persistent injection-site swelling was reported in 25% of patients on SAs compared with 
2% of patients on placebo. In one trial, doses of SA were reduced in 7 patients, mainly due 
to gastrointestinal side effects.13 In contrast, no patients in the placebo group required a 
dose reduction. Mean fasting plasma glucose levels increased from 5.2 mmol/L (95% CI: 
5.1 - 5.4 mmol/L) to 5.6 mmol/L (95% CI: 5.4 - 5.8 mmol/L) in the SA group. In contrast, 
 
Patient group  
SA v s baseline , % change  
(95% CI)  
Placebo v s baseline , % 
change  (95% CI)  
SA v s placebo , % change  
(95% CI)  
 
P-value  
Interaction 
(P value)  
Age
a
- Sex
  Women  
      48 y  or younger  
      Older than  48 y  
   Men  
      48 y  or younger  
      Older than  48 y  
 
 
-3.5 ( -5.6 to -1.5 ) 
-3.5 ( -6.0 to -0.9 ) 
 
-3.5 ( -7.4 to 0.6 ) 
-2.6 ( -5.9  to 0.8)  
 
 
4.8 (2.2 to 7.4 ) 
0.6 ( -2.5 to 3.8 ) 
 
-1.8 ( -6.2 to 2.8 ) 
0.5 ( -3.3  to 4.5 ) 
 
 
-8.0 ( -10.6 to -5.2 ) 
-4.1 ( -7.4 to -0.6 ) 
 
-1.8 ( -7.2 to 4.0 ) 
-3.1 ( -7.8 to 1.9 ) 
 
 
<.001  
.022  
 
.53  
.22  
trend (.084)  
Table 4: Outcomes in age-sex subgroups: estimated mean percent changes in liver volumes after 6-12 months, 
calculated by multiple linear regression analysis
NA, not applicable. aAge groups defined by the median as the cut-off value. 
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fasting glucose levels remained stable in the placebo group, with an increase from 5.2 
mmol/L (95% CI: 5.0 - 5.3 mmol/L) to 5.1 mmol/L (95% CI: 4.9 - 5.3 mmol/L). Although 
this difference was significantly different between both treatment groups (P = .005), no 
patient developed diabetes or required antidiabetic therapy. 
Discussion
The key finding of our IPD pooled analysis is that underlying diagnosis (ADPKD or PCLD) 
and liver size had little influence on the significant liver volume-reducing effect of SAs in 
PLD patients. However, untreated young women (48 years old and younger) in particular 
have the largest increase in polycystic liver volume (+4.8%) and responded best to SA 
therapy (-8.0%) when compared with placebo.
We did not find a significant interaction between polycystic liver size at baseline and 
treatment allocation, suggesting the benefit of SA therapy was similar for all polycystic 
liver sizes. This seems in contrast to the individual results of 2 trials that were included 
in our analysis, where both trials observed that larger livers had more volume reduction 
than smaller livers. 13, 14 However, these trials assessed absolute change in liver volume 
instead of percent changes and did not include a comparison with a placebo group, which 
might lead to biased results.
We observed that polycystic livers grow significantly faster in PCLD patients compared 
with ADPKD patients. One observational study compared the natural course of PLD in 
34 ADPKD and 19 PCLD patients and showed that PCLD patients had significant greater 
number and larger size of liver cysts.22 The more progressive course in PCLD may be 
explained by differences in expression of underlying genetic mutations, although there is 
no experimental evidence supporting this hypothesis.
Based on our analysis, the growth rate of polycystic livers is estimated at 1.8% in 6-12 
months. The observed liver growth of 4.8% in young women is a clear departure from the 
growth rate in older women and men of all ages (0.6% and -0.1%), strongly suggesting 
a hormonal influence. This hypothesis is supported by previous studies that established 
multiple pregnancies and exogenous estrogens as risk factors for growth of hepatic 
cysts.23, 24 In addition, 1 year of postmenopausal estrogen therapy increased polycystic 
liver volume 7% in ADPKD women; liver volumes did not change in controls.25 However, 
none of the included patients in our study were pregnant or used oral contraceptives, 
suggesting premenopausal status in women is an independent risk factor for polycystic 
liver growth. Cholangiocyte proliferation is considered one of the major contributors to 
hepatic cystogenesis and is significantly increased by estrogens in vitro.2, 26, 27 Unfortunately, 
it was not possible to investigate whether the increase in liver growth also aggravated 
symptoms in these patients, as only one study evaluated change in symptoms.14 
The effect of SA therapy was most pronounced in women 48 years old or younger. The 
beneficial response might be caused by averting the progressive course of PLD observed 
in these patients, thereby suggesting that therapy is more effective in fast-growing 
polycystic livers. However, the increased liver growth in PCLD patients compared with 
ADPKD patients did not lead to an increase in treatment effect (-5.6% vs -5.2%), indicating 
that other factors might be involved. One study showed that the efficacy of octreotide 
to suppress cyclic adenosine monophosphate accumulation in female rat pituitary cells 
increased after treatment with 17 β-estradiol.28 This suggests that estrogens, apart from 
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increasing cholangiocyte proliferation, might also enhance the ability of SAs to inhibit cyclic 
adenosine monophospate production in cholangiocytes, and can increase susceptibility 
to SA therapy in fertile women. To evaluate whether this mechanism is of importance 
in hepatic cystogenesis, this result must first be reproduced in a cholangiocyte cell line. 
As such, our results may lend credence to the concept that short-term SA therapy benefits 
young female PLD patients in particular. In addition, our results provide extra support 
for avoidance of other risk factors (ie, exogenous estrogens) for young female PLD and 
PCLD patients in particular, as these individuals already may have a more progressive 
disease course. The failure to detect a significant positive effect of SA therapy in male 
PLD patients is possibly due to the low number of these patients. Therefore, we think it 
is premature to withhold therapy from this subgroup, especially as there are individual 
male PLD patients who are responding. If clinicians want to replicate these results in 
clinical practice, they have to follow the inclusion criteria used in the RCTs and become 
familiar with the side-effect profile and guidelines for the prescribing these drugs in the 
context of renal insufficiency. In addition, the findings presented here only apply for 
a short treatment regimen of 6-12 months. Extension of SA therapy beyond this time 
period might result in improved, or maintenance of, treatment effects, as 2 recent 
extensions of 2 of the included RCTs have shown.29, 30 One extension trial demonstrated 
that 6 months of lanreotide (120 mg injected monthly) resulted in a 4.0% reduction 
in liver volume from baseline, which was maintained for the remainding 6 months of 
therapy.29 Similarly, another extension trial demonstrated that the effect of octreotide 
(40 mg injected monthly) was -5.2% in the first 12 months, and that this reduction did 
not change significantly after another 12 months of therapy (-0.8%, P = .57).30 Although 
both extension trials did not include a control group, these findings indicate that SAs 
curtail polycystic liver growth up to 2 year. In addition, discontinuation resulted in 
immediate recurrence of liver growth, suggesting that continuous treatment is necessary 
to maintain this beneficial effect.29 Given the expense of treatment, it is paramount to 
establish on-treatment effects that would warrant long-term therapy. As the natural 
course of PLD varies between PLD patients, it is insufficient to look at a fixed threshold of 
liver volume reduction alone. Therefore, we suggest determining the (semi-)annual liver 
growth rate in a PLD patient before initiating SA therapy, which can be compared with the 
on-treatment effects of SA. If this effect is smaller than a certain threshold, SA therapy 
should be discontinued. Ideally, this threshold is correlated to a clinical significant effect, 
for example, symptom resolution. Points of discussion are how to handle patients without 
a progressive course of PLD or with aggravation of symptoms during therapy. 
The current treatment strategy for PLD includes laparoscopic fenestration, partial 
hepatectomy, and liver transplantation, and is indicated in symptomatic patients.1, 31, 32 
If a patient has several large superficial liver cysts, laparoscopic fenestration is the best 
therapeutic choice. Partial hepatectomy can be considered if patients have cyst-rich 
segments with at least one segment spared, and liver transplantation is only indicated in 
patients with a severely impaired quality of life or untreatable cyst-related complications. 
Before including SA therapy into the existing treatment strategy, it is important to be 
familiar with recurrence rates and complications of long-term use of SAs and how they 
relate to established surgical options. Addressing these questions will provide more 
insight in which patients will benefit from long-term treatment with SAs or surgery. At 
this time, SA therapy may be only considered in highly symptomatic patients that are not 
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eligible for surgical intervention. Future roles for SAs include delaying the need for liver 
transplantation or combined with surgery to optimize clinical results.
The main strength of our study is that we included the individual patient data of all RCTs 
that compared SA with placebo in PLD patients. In addition, the wide range in baseline 
characteristics among included RCTs allowed us to thoroughly investigate the influence 
of these characteristics on therapeutic response. Although one study was a post-hoc 
analysis on a cross-over trial12, none of the included studies had a high risk of bias for one 
or more key domains. Almost all patients completed the trial with only 1 dropout in the 
placebo group. A sensitivity analysis using the baseline liver volume of this patient as the 
end point showed no differences with the original analysis, indicating that exclusion of 
this patient did not influence our findings. 
Study limitations include the 2 types of SA (octreotide and lanreotide) that were investigated 
in our IPD pooled analysis. To our knowledge, no study has directly compared the efficacy 
of lanreotide and octreotide in PLD patients. The average effects of SA therapy in all 
included RCTs were very similar, suggesting that the efficacy of octreotide and lanreotide 
is comparable in PLD. Several studies in patients with acromegaly reported comparable 
effects of long-acting lanreotide and octreotide, thereby indicating that that these drugs 
share pharmacodynamic profiles.33, 34 One of the included RCT had a cross-over design 
and did not include a washout period between the 2 arms.12 However, the observed 
treatment effect was independent of treatment sequence in this trial, thereby excluding 
any considerable carry-over effect. The duration of included trials were not similar, as 2 
trials evaluated the effect of SA therapy in 6 months12, 14 and 1 trial had a follow-up of 1 
year.13 We performed a sensitivity analysis that showed no notable differences in effect 
of placebo and SAs on change in liver volume between 6 and 12 months of follow-up. 
These findings indicate that the 6-month and 12-month data could be aggregated in our 
IPD pooled analysis. In addition, to control for the possible differences in methodological 
designs between the included RCTs, including differences in follow-up time, we included 
study as a variable in our IPD pooled analysis.
 
In conclusion, we show that in patients with PLD, SA therapy is equally effective in ADPKD 
and PCLD patients; the size of the polycystic liver does not affect the response to SAs; 
young female patients (48 years old and younger) have the largest growth in liver volume 
in 6-12 months, and seem to have the most substantial effect of SA therapy. Additional 
large-scale multicenter studies evaluating the long-term effects of SAs on liver volume 
and symptom resolution in PLD patients are necessary to substantiate the merits of this 
therapy.
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Supplementary files
Adverse event Somatostatin analogue n/Na (%) Placebo n/Na (%) 
Diarrhea/Loose stools 34/67 (51) 7/52 (13) 
Abdominal cramps 23/67 (34) 1/52 (2) 
Flatulence, bloating and gas 20/67 (30) 3/52 (6) 
Persistent injection site swelling 17/67 (25) 1/52 (2) 
Steatorrhea 10/67 (15) 0/52 (0) 
Nausea 9/67 (13) 3/52 (6) 
Constipation 4/67 (6) 1/52 (2) 
Supplementary Figure 1: Flow diagram of selection articles.
Supplementary Figure 2: Percent changes in liver volume for all treatment periods. Each bar represents 1 
treatment period (n=119).
aDenominator is total of patients in treatment arm
Supplementary table 1: Adverse events
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Supplementary Figure 3: 
Estimated percent changes 
(mean ± 95% CI) in liver 
volume in all patients 
treated with somatostatin 
analogues or placebo for 
6-12 months, calculated by 
linear multiple regression 
analysis. 
Supplementary Figure 4: 
Estimated percent changes 
(mean ± 95% CI) in liver 
volumes in men and women 
treated with somatostatin 
analogues or placebo for 
6-12 months, calculated by 
multiple linear regression 
analysis. 
Supplementary Figure 5: 
Estimated percent changes 
(mean ± 95% CI) in liver 
volumes in age subgroups 
(median of 48 years as a 
cut-off value) treated with 
somatostatin analogues or 
placebo for 6-12 months, 
calculated by multiple 
linear regression analysis. 
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Abstract
Background&Aims 
Somatostatin analogues reduce liver volumes in polycystic liver disease. However, 
patients show considerable variability in treatment responses, making it difficult to 
predict response to therapy. Our aim was to identify specific patient, disease or treatment 
characteristics that predict response in polycystic liver disease during somatostatin 
analogue therapy. 
Methods
We pooled the individual patient data of 4 trials that evaluated long-acting somatostatin 
analogues (120 mg lanreotide or 40 mg octreotide) for 6 or 12 months in polycystic liver 
disease patients. We performed uni- and multivariate linear regression analysis with 9 
preselected patient, disease and drug variables to identify independent predictors of 
response, defined as percent change in liver or kidney volume (in ADPKD subgroup). All 
analyses were adjusted for baseline liver volume and center.
Results
We included 153 polycystic liver disease patients (86% female, mean age 50 years, median 
liver volume 4974 ml) from 3 international centers, all treated with octreotide (n=70) or 
lanreotide (n=83). Mean reduction in liver volume was 4.4% (range -31.6% to +9.4%). 
Multivariate linear regression revealed that elevated baseline alkaline phosphatase was 
associated with increased liver volume reduction during therapy (-2.7%,95% CI -5.1% 
to -0.2%,p=0.04), independently of baseline liver volume. Somatostatin analogue type, 
underlying diagnosis and eGFR did not affect response. In our ADPKD subpopulation 
(n=100), elevated alkaline phosphatase again predicted liver volume reduction 
(-3.2%,p=0.03) but did not predict kidney volume reduction (+0.1%, p=0.97). 
Conclusion
Elevated alkaline phosphatase is a liver-specific, independent predictor of response in 
polycystic liver disease during somatostatin analogue therapy.
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Introduction
Polycystic liver disease (PLD) is common in patients with autosomal dominant polycystic 
liver disease (PCLD)1, 2 and autosomal dominant polycystic kidney disease (ADPKD).3 The 
progressive enlargement of the liver causes chronic symptoms and results in reduced 
quality of life in these patients.4 Somatostatin analogues (SAs), such as lanreotide and 
octreotide, are cyclic adenosine monophosphate (cAMP) level inhibitors and decrease 
polycystic liver volume.5, 6 Recently, a recent meta-analysis showed that 6-12 months 
of SAs decreased polycystic liver volume with 5.3% in PLD patients when compared to 
placebo.7 This clearly supports the thesis that growth of polycystic liver can be suppressed 
by SAs. 
While the overall majority of PLD patients respond to SAs therapy, there is great 
interindividual variability which makes it difficult to predict which patients will respond 
favorably. This can be due to patient related factors as it has been suggested that patients 
with larger polycystic livers had higher reductions in absolute liver volume in two studies 
that evaluated lanreotide in PLD.8, 9 Likewise pharmacokinetic factors such as body weight 
or renal function may influence pharmacodynamic properties of SA.10 On the other hand 
exogenous factors such as different SA types may affect treatment responses. Finally, 
liver enzymes including alkaline phosphatase (ALP), gamma-glutamyl transferase and 
bilirubin are elevated in PLD patients and may be associated with disease progression.11, 12 
By identifying specific patient, disease or treatment related characteristics that are 
associated with response, we can select patients that will have higher success rates on 
therapy. This will allow for a more individualized therapy preventing unnecessary and 
ineffective SA therapy. Furthermore, identifying predictors of response will provide more 
insight in how these factors affect liver volume progression in PLD. Unfortunately, the 
small number of patients from individual studies precluded the analysis of predictors. 
We therefore performed a pooled analysis on individual patient data of four trials that 
evaluated SA therapy in PLD patients to overcome this limitation.  
In this study, we investigate which patient, disease and treatment factors are 
independently associated with response in PLD patients, and explore the relationship 
between these factors and liver volume progression during SA therapy. 
Methods
Population
We included the individual patient data (IPD) coming from 4 trials that described the 
effect of long-acting SAs (120 mg lanreotide or 40 mg octreotide) for 6 or 12 months in 
adult PLD patients and had change in liver volume as the primary outcome. We contacted 
the authors from the following trials for inclusion of data: LOCKCYST trial + extension 
(NCT00565097/ NCT00771888) 9, 13, Mayo Clinic trial + extension (NCT00426153) 14, 15, 
ELATE trial (NCT01157858) 16 and RESOLVE trial (NCT01354405) 17. In the LOCKCYST trial, 
54 patients with PLD (ADPKD n=32; PCLD n=22) were randomized to monthly injections 
of lanreotide 120 mg or placebo for 6 months. Treatment was extended to a total of 
12 months in 41 of 54 PLD patients in the LOCKCYST extension study. The Mayo Clinic 
trial evaluated the effect of long-acting octreotide 40 mg given monthly for a year in 42 
patients with ADPKD (n=34) or PCLD (n=8). Patients were randomized 2:1 to octreotide 
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and placebo respectively. The Mayo Clinic trial also extended SA therapy with 1 year 
for 41 of the 42 patients, which enabled patients in the placebo arm to be treated. The 
ELATE trial randomized 44 patients (combined ADPKD and PCLD) to octreotide combined 
with everolimus or to octreotide monotherapy. Because the difference in liver volume 
changes was not significant between the two treatment arms (p = 0.73), we included 
patients from both treatment arms. Finally, the RESOLVE trial investigated the effect 6 
months of lanreotide in 43 ADPKD patients in an uncontrolled study.  
All study protocols of included trials conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the institution’s human research 
committee, and all patients who participated in the studies provided written consent.
Data Acquisition 
We sent an electronic form containing the data fields to be completed for individual 
patients to all principal investigators of the trials. The primary author (T.G) pooled all 
data, checked databases for completeness and internal consistency and made corrections 
through correspondence with the investigators. We included all PLD patients with ADPKD 
or PCLD as the underlying disease and received SA therapy for more than 3 months in 
one of the 4 aforementioned trials. We collected liver and kidney volumes at baseline 
and end of therapy. We obtained the following candidate predictors at baseline: sex, 
age, diagnosis, weight, estimated glomerular filtration rate (eGFR), SA type (lanreotide 
or octreotide), ALP, gamma-glutamyl transferase and bilirubin. In addition, everolimus-
cotherapy and length of SA therapy were recorded. In case the patient participated in 
multiple trials, only the first trial period was included in the analysis. 
Outcome definitions
The primary outcome was response defined as change in liver volume at end of therapy 
compared to baseline. Liver volumes were calculated by CT- or MRI volumetry as 
described in detail elsewhere.9, 15, 18 All CT and MRI scans were blinded to patient identity, 
date of birth and date of scan at time of measurement. As liver volumes were measured 
at different follow-up time points, we aggregated the data at 6 months and 12 months of 
follow-up. Secondary outcomes was change in kidney volume at end of therapy compared 
to baseline. The adjusted Ravine criteria were used to diagnose ADPKD; if patients did not 
fulfill the criteria, they were diagnosed as PCLD.19 The patient’s age was determined at 
time of the baseline CT or MRI. We dichotomized weight to < or ≥ 75 kg, using the mean 
as a cut-off. eGFR was assessed by using the 4-variable MDRD formula, and we included 
eGFR both continuous and dichotomized to < 60 or ≥ 60 ml/min/1.73m2.20 ALP, gamma-
glutamyl transferase and bilirubin were dichotomized to either elevated or normal. 
Because different cut-offs were used for ALP in laboratories, we compared ALP levels 
to the upper limits of normal (ULN) and calculated as a ratio. ALP was considered to be 
elevated if levels at baseline were greater than a ratio of 1 and considered to be normal 
if the values had a ratio of 1 or less.
Statistical analysis
The IPD pooled analysis was conducted according to the intention-to-treat principle. 
As liver volumes have a skewed distribution, we first calculated the logarithms of liver 
volumes and then carried out the analyses. Effect estimates were backwards transformed 
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and the results were presented as mean percentage differences, with 95% confidence 
intervals (CI). We performed univariate and multivariate linear regression to determine 
which variables were associated with the outcome liver volume. Variables with p < 0.2 
in the univariate analysis were selected for the multivariate analysis. We used backward 
selection to exclude variables in the multivariate analysis, variables with a p-value of 
0.05 retained in the model. We included the variable center as a random effect in all 
analyses to take into account the heterogeneity among the different centers. In addition, 
we adjusted for baseline liver volume in all analyses. 
In order to check whether we could aggregate the 6 and 12 months treatment data, we 
added treatment duration (6 vs 12 months) of SA therapy to the final model. Similarly, we 
performed analysis using everolimus co-therapy as an independent variable to investigate 
whether everolimus co-therapy was associated with response. 
For the secondary outcome change in kidney volume, we performed multivariate linear 
regression analysis in ADPKD patients. We included all significant predictors from the 
primary multivariate analysis as independent variables and adjusted for baseline kidney 
volume.
To determine the probabilities of achieving a good response, defined by different cut-
offs in change in liver volume, we performed logistic regression analysis, including good 
response (yes/no) as the outcome and all significant predictors in the primary analysis as 
independent variables.
All statistical analyses were performed with SPSS statistical software package version 
20.0 (SPSS Inc., Chicago, IL) by TG. All P-values calculated were 2-tailed, and the level of 
significance was set at alfa = .05
Role of Funding Source
This study was not supported by any company or grants. The costs were borne by the 
authors’ institutions.
Results
We selected 155 of a total of 183 trial episodes for our study; the remainder was excluded 
due to participation in multiple trials (n=28). Two more patients were excluded because 
they were on placebo while participating; no patient was excluded because they received 
< 3 months of SA therapy. The general characteristics of the 153 individual patients 
included in our study population are reported in table 1. Overall, most patients had severe 
PLD (median liver volume 4974 ml), were female (86%) and received SA therapy for 12 
months. The majority of patients had ADPKD as the underlying diagnosis (105 ADPKD 
versus 48 PCLD). Seventy patients were treated with octreotide LAR 40 mg, whereas 83 
PLD patients received lanreotide 120 mg every 4 weeks.  For analysis of kidney data, 53 
patients were excluded because of a diagnosis of PCLD (n = 48), renal transplantation (n = 
4) or incomplete image coverage of kidneys (n = 1). None of the patients underwent liver 
surgery or transplantation during the trial. 
Primary outcome – change in liver volume
Median liver volume decreased from 4974 to 4787 ml in the study population (n=153) 
after 6-12 months, resulting in a mean change in liver volume of -4.2%. Responses ranged 
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Table 1: General characteristics
a Only ADPKD patients
b Included the 111 patients with measured gamma-glutamyl transferase at baseline
from -31.7% to +9.5% in individuals. 
The results of the univariate analysis are reported in Table 2. Baseline age, weight, sex, 
SA type, eGFR and bilirubin status (elevated versus normal) did not affect response 
during SA therapy in the univariate analysis. Both diagnosis (PCLD vs ADPKD; -1.7%; p 
= 0.15) and baseline ALP status (elevated vs normal; -2.7%; p = 0.04) were selected for 
the multivariate analysis. Multivariate linear regression revealed that elevated ALP status 
at baseline was a significant predictor of liver volume reduction (-2.7%, 95% CI -5.1% to 
-0.2%, p = 0.04) during SA therapy, whereas diagnosis did not reach statistical significance 
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Figure 1: Liver volume reduction according to ALP status. Percent 
changes in liver volume in 153 PLD patients with normal (n = 105) and 
elevated ALP (n = 48) at baseline. Data is shown in mean and 95% CI. 
Patients, n 153
Trial, n (%) 
   LOCKCYST + extension  
   MAYO + extension    
   ELATE 
   RESOLVE 
 
51 (33) 
42 (28) 
32 (21) 
28 (18) 
Center, n (%) 
   Radboudumc 
   University Hospital Leuven 
   Mayo clinic Rochester 
 
87 (57) 
24 (16) 
42 (28) 
Age, y, mean (range) 50 (32 – 70) 
Weight, mean (range) 75 (50 -130) 
Diagnosis (ADPKD/PCLD) 105/48  
Gender (female/male) 132/21  
Liver volume, ml, median (range) 4974 (1300 – 15320) 
Kidney volume, ml, median (range)a 945 (267 – 4566) 
Compound (lanreotide/octreotide) 83/70 
Everolimus co-therapy (yes/no) 10/143 
Duration of SA therapy (6 mo/12 mo) 43/110 
Kidney transplantation (yes/no) 4/148 
eGFR, ml/min/1.73m2, mean (range) 70 (19 – 124) 
ALP times normal, median (range) 0.8 (0.4 – 5.7) 
Elevated ALP (yes/no) 48/104 
Bilirubin, µmol/L, median (range) 10 (5 – 33) 
Elevated bilirubin (yes/no) 12/141 
Gamma-glutamyl transferase, U/L, median (range)b 78 (17 – 555) 
Elevated gamma-glutamyl transferase (yes/no) 85/26 
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Table 2: Univariate and multivariate analysis
a All analyses are adjusted for center and baseline liver volume
b These variables were included separately to the final multivariate model
c Included the 111 patients with measured gamma-glutamyl transferase at baseline
(-1.3%, 95% CI -3.6% to +1.1%; p 0.28). Indeed, mean liver volume reduction was 6.1% 
(95% CI 2.0% to 4.5%) in patients with elevated ALP, whereas volumes decreased with 
3.3% (95% CI 4.5% to 7.7%) in patients with normal ALP (Figure 1). Because baseline liver 
volume possibly impacted the association between baseline ALP status and change in 
liver volume, we also checked for interaction, which was absent (p = 0.58).     
Next, we added length of treatment and everolimus co-therapy to the multivariate 
model to test whether these variables affected the primary outcome (Table 1). Treatment 
duration (12 versus 6 months) was not associated with increased response (-0.7%, 95% 
CI -3.3% to +2.0%; p = 0.62) in our study population, which supports the decision to 
aggregate data from the 12 and 6 month treatment studies. Everolimus co-therapy did 
not affect response during SA therapy (p = 0.47). 
Because elevated alkaline phosphatase is also associated with renal osteodystrophy in 
patients with chronic renal failure, we excluded all patients that had kidney transplantation 
or had an EGFR < 30 ml/min/1.73m2 (n = 11) at baseline. Elevated ALP remained associated 
with response during SA therapy (-3.0%, 95% CI -5.5% to -0.4%; p = 0.03).
Although gamma-glutamyl transferase was not measured in one of the included trials, 
we checked whether it affected the response in liver volume in the remaining 111 PLD 
patients by including gamma-glutamyl transferase in the multivariate model. Elevated 
gamma-glutamyl transferase at baseline did not significantly increase the response in 
liver volume (-1.9%, 95% CI -4.6% to 0.9%; p = 0.18). 
Secondary outcome- change in kidney volume
Median kidney volume decreased from 945 to 932 ml In the 100 ADPKD patients included 
in the kidney analysis, corresponding with a change of -0.6% (range -15.6% to +22.5%). 
Variable Univariatea 
% change (95% CI) P value
Multivariate
% change (95% CI) P value
Age (y), continuous 0.0 (-0.1 to 0.2) 0.60 
Sex, male vs female  1.8 (-1.4 to 5.1) 0.27 
Diagnosis, PCLD vs ADPKD -1.7 (-4.0 to 0.7) 0.15  -1.3 (-3.6 to 1.1) 0.28 
Weight (kg), continuous 0.0 (-0.1 to 0.1) 0.58 
Weight (kg), ≥ or < 75 kg 0.3 (-2.0 to 2.7) 0.77 
SA type, octreotide vs lanreotide -1.2 (-4.0 to 1.6) 0.39 
eGFR (ml/min/1.73m2), continuous 0.0 (-0.1–0.0) 0.32 
eGFR (ml/min/1.73m2), ≥ or < 60 1.2 (-1.2 to 3.7) 0.34 
-2.7 (-5.1 to -0.2) 0.04 -2.7 (-5.1 to -0.2) 0.04 
Bilirubin, elevated vs normal 2.6 (-1.6 to 6.9) 0.23 
Sensitivity analyses b 
Duration of therapy, 12 vs 6 months  -0.7 (-3.3 to 2.0) 0.62 
Everolimus co-therapy, yes vs no -1.5 (-6.1 to 3.3) 0.52 
Gamma-glutamyl transferase, 
elevated vs normalc 
-1.9 (-4.6 to 0.9) 0.18 
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Multivariate regression analysis again showed that elevated ALP predicted liver volume 
reduction (-3.2%, 95% CI -6.0% to -0.3%, p = 0.03) in this subgroup, whereas it did not 
predict kidney volume reduction (+0.1%, 95% CI -3.1 to +3.3%, p = 0.97). Indeed, mean 
decrease in kidney volume was similar in ADPKD patients with (n = 24) and without (n = 
76) elevated ALP at baseline (-0.2% versus -0.7%; Figure 2A), whereas elevated ALP status 
was still associated with increased reduction in liver volume (-6.3% versus -3.0%; Figure 
2B). 
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Figure 2: Liver and kidney volume reduction in ADPKD 
subpopulation according to ALP status. Percent 
reduction in kidney (A) and liver volumes (B) in 100 
ADPKD patients with normal (n = 76) and elevated ALP 
(n = 24) at baseline. Data is shown in mean and 95% CI.
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Figure 3: Probability of achieving a good response 
during SA therapy, stratified for ALP status. This figure 
shows the probability of achieving a good response 
during SA therapy using different cut-offs for liver 
volume reduction. For every cut-off of liver volume 
reduction, there is a higher probability of achieving this 
reduction when the patient has an elevated ALP.  For 
example, if you set a reduction of 5% in liver volume as 
the threshold for response during SA therapy (dotted 
line), the probability of achieving this response will be 
58% for patients with elevated ALP (dashed line) and 
31% for patients with normal ALP (connected line).   
Probability for good response
We checked whether ALP status also affected the probability of achieving a good 
response,  defined by using different cut-offs for reduction in liver volume (figure 3). As 
expected, the probability of achieving a good response decreases when the cut-off for 
good responder is set at a higher threshold. Elevated ALP status increased the chance of 
becoming a good-responder compared with normal ALP status for all cut-off values. For 
example, when a reduction of 5% in liver volume is used as a cut-off for good-response 
during SA therapy, the probability of achieving a good-response will be 58% for patients 
with elevated ALP at baseline, whereas it will be 31% for patients with normal ALP.
Discussion
The main finding of our study was that baseline elevated ALP increased liver volume 
reduction in PLD patients during SA therapy, whereas it did not predict kidney volume 
reduction. SA type, underlying diagnosis and eGFR did not affect responses to SA therapy. 
The target cell in PLD is the cholangiocyte. While the exact function of ALP is to be 
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elucidated there is evidence to suggest that ALP affects the secretory function of 
cholangiocytes. The apical membrane of cholangiocytes are continuously exposed to 
high ALP concentrations and one study showed that administration of ALP to bile duct 
ligated rats decreased basal and secretin stimulated bile flow and biliary bicarbonate 
secretion.21 The authors suggested that ALP could counterregulate secretory stimulation 
of cholangiocytes, thereby preventing further increase in bile pressure during obstructive 
cholestasis.21 
ALP could exert a similar role in PLD, counteracting fluid secretion from cholangiocytes 
lining the hepatic cysts, thereby enhancing the effect of SAs on cAMP-dependent chloride 
and fluid secretion.22, 23 The conjecture is that elevated ALP plays a protective role in PLD. 
However, since all patients received SA therapy in this cohort, it remains unclear whether 
ALP also predicts liver volume reduction in untreated patients. 
Several studies found elevated ALP levels in PLD patients (15% to 47%), similar to the 
proportion (31%) observed in our study.12, 24, 25 The increase in ALP in PLD probably 
reflects cholangiocyte activation.26 In these retrospective studies, patients with elevated 
ALP were more likely to have an indication for liver transplantation12 or to have invasive 
treatment, which suggest a worse prognosis instead of the improvement in liver volume 
we observed25. However, findings in these studies were not adjusted for baseline liver 
volume. In our cohort, only 13% of patients with a baseline liver volume of less than 3 
Liter (25th percentile) had elevated ALP at baseline, in contrast to 60% in patients with a 
baseline liver of more than 7 Liter (75th percentile). It is therefore more likely that in these 
retrospective studies the need for therapy was set by severe hepatomegaly rather than 
the elevated ALP. Our study clearly shows that elevated ALP predicted response in liver 
volume during SA therapy independently of baseline liver volume. 
Whether a better response also translates results in improvement of symptoms remains to 
be elucidated. Unfortunately, we could not investigate patient reported outcomes in our 
study because different QoL questionnaires were used in the included trials. In addition, 
the generic gastrointestinal symptom questionnaire used in some of the trials did not 
adequately capture and detect changes in PLD related symptoms over time. Recently, 
a polycystic liver disease specific questionnaire is developed which is more sensitive to 
change in PLD-specific symptoms than the generic SF-36.27 This questionnaire can be 
used in future studies to investigate whether our findings also affect clinical responses.
SA type (octreotide or lanreotide) was not associated with change in response in our 
study. This is in line with the results of a recent meta-analysis that compared the effect 
of SA with placebo in PLD patients.7 Although the clearance of somatostatin analogues 
partly depends on renal function, we did not find a relation between eGFR or ADPKD 
diagnosis and change in liver volume in our study. 10 However, most ADPKD patients in our 
study did not have severe renal insufficiency, which precludes a thorough investigation.     
Our results indicate that elevated ALP can serve as a liver-specific biomarker for response 
in patients requiring SA treatment. At this moment, SAs are used off-label or in the context 
of clinical trials to highly symptomatic patients unfit for surgical therapies.28 Given the 
high costs of SAs, it is preferable to initiate treatment in those patients that will have a 
high probability for achieving a response. The ALP status can help decide whether to start 
SA therapy in these patients, thus preventing unnecessary treatment in other patients. 
Our results need to be confirmed in patients receiving SA therapy over 1 year to confirm 
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that ALP status also predicts long-term outcomes.
The major strength of our study is that we have collected the largest group to date of 
individual PLD patients that received long-acting SA therapy for 6-12 months, which 
enabled us to investigate factors associated with increased response. All included 
patients were symptomatic or had severe PLD and from different international centers, 
thus reflecting the patient population that requires treatment. This increases the 
generalizability of our findings to this group of PLD patients.  
A limitation in our study was that we aggregated 6 and 12 months data. However, a 
sensitivity analysis showed that treatment duration did not affect the change in liver 
volume. In addition, one of the included studies showed that the decrease in liver volume 
mainly occurs in the first 6 months, and stabilizes between 6 and 12 months.13 Second, 
we did not determine ALP isoenzyme typing to exclude other causes of ALP elevation, 
including increased osteoblastic activity due to renal osteodystrophy in chronic kidney 
disease.29 However, elevated ALP remained a significant predictor for response when 
ADPKD patients at high risk for renal osteodystrophy (eGFR < 30 ml/min/1.73m2 or kidney 
transplantation) were excluded. In addition, 97% of patients with elevated ALP had also 
an elevated gamma-glutamyl transferase, which makes a hepatic origin of ALP very likely. 
In conclusion, elevated ALP is a liver-specific, independent predictor of response in 
patients with PLD during SA therapy. ALP could serve as a prognostic biomarker in PLD 
patients requiring SA treatment.   
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General discussion
Currently available treatment options for symptomatic polycystic liver disease (PLD) are 
aimed at surgical reduction of liver volume.1 Although these therapies are successful in 
selected patients, they cause significant morbidity and mortality, and most importantly, 
are unable to change the natural course of the disease.2, 3 In many PLD patients with 
massive hepatomegaly, liver transplantation remains the only treatment option. Although 
survival after liver transplantation is good compared with other liver disease patients, 
there is still a high mortality rate of 8% in 5 years.1, 4 
This has led to the introduction of somatostatin analogues as treatment option for PLD 
(chapter 2). In the last few years, several trials demonstrated the beneficial effects of 
somatostatin analogues on liver volume in patients with PLD.5-10 However, given the 
overall modest effect of therapy, unknown side-effects profiles in subgroups and the 
uncertainty who will respond, it is still unclear which patients should be treated with this 
drug.  
We investigated several patient, disease and treatment factors that may affect outcomes 
in PLD patients receiving somatostatin analogues. The goal of this thesis was to identify 
PLD patients that benefitted most from somatostatin analogue therapy, in order to 
individualize the treatment approach in these patients. 
Answers to research questions
Research question 1: Are somatostatin analogues effective and safe in ADPKD patients?
We demonstrated that 6 months of lanreotide reduced liver and kidney volumes in 
ADPKD patients and decreased postprandial fullness, shortness of breath and abdominal 
distension (chapter 3a&b). These findings are in line with other studies that evaluated 
octreotide in ADPKD patients, although these studies did not evaluate symptoms and 
quality of life.11, 12 In addition, estimated glomerular filtration rate (eGFR) decreased in 
the first 4 weeks, stabilized thereafter and declined again after withdrawal of lanreotide. 
Our results support the hypothesis that lanreotide is effective in reducing liver and 
kidney volumes in patients with ADPKD, and suggests a protective role of lanreotide in 
deterioration of renal function. However, the short follow-up and the lack of a control 
group precluded definite conclusions on renoprotective effects of lanreotide.  
We did not find an effect of somatostatin analogue therapy on health-related quality 
of life in this study. Possible explanations are that reductions in liver volumes and 
symptoms were too small to result in a change in quality of life, or that the EQOL-5D 
was unable to detect the tangible changes in quality of life. Indeed, recent studies have 
demonstrated the low responsiveness of the EQOL-5D for detecting disease progression 
and treatment response in other chronic conditions.13, 14 In retrospect, the SF36 would be 
more appropriate to include as a quality of life endpoint, as several studies showed that 
this questionnaire can detect decreased quality of life in patients with PLD.15, 16 
Lanreotide was well tolerated in ADPKD patients, even in the context of reduced eGFR. 
Three patients were suspected of hepatic or renal cyst infection during our study, all with 
a history of cyst infections. This number seems high compared with the incidence of cyst 
infections in ADPKD of one per 100 patients per year.17 Although cyst infections have 
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never been related to somatostatin analogues, some animal studies have shown that 
somatostatin analogues can induce bacterial translocation from the gut.18, 19 Whether 
this also results in an increased risk for developing a cyst infection during somatostatin 
analogue therapy needs to be investigated. 
Research question 2: Are there certain patient or disease subgroups with increased 
responses to somatostatin analogue therapy?
We demonstrated that young female patients (48 years and younger) show the largest 
response after 6-12 months of somatostatin analogue therapy compared with placebo 
in chapter 4. This large effect is mainly caused by counter-acting the increase in liver 
volume observed in untreated young women. The observation that female sex is a risk 
factor for a more severe phenotype is in line with findings of other studies. One study 
showed that females PCLD patients had higher frequency of liver cysts compared with 
men, whereas in another study including 238 ADPKD patients the number and size of 
hepatic cysts was correlated with female sex. 20, 21 Both these studies had a cross-sectional 
design, and thus were unable to explore the relation between gender and polycystic liver 
disease progression. Only one other study investigated liver enlargement prospectively 
in PLD patients, and showed that postmenopausal estrogen replacement was associated 
with selective liver enlargement in ADPKD patients.22 We are the first to demonstrate that 
female gender is associated with increased progression in liver volume, independent of 
exogenous estrogen use or pregnancies, and that somatostatin analogues are able to 
reverse this process.  
We also discovered that underlying diagnosis (ADPKD or PCLD) and liver size did not 
affect the treatment efficacy of somatostatin analogues in PLD patients. The absence of a 
relation between liver volume and treatment effect is in contrast with previous trials that 
showed that larger livers had more liver reduction than smaller livers.5, 9 However, these 
trials investigated absolute liver volume reduction instead of percent changes. Given the 
large range in liver volumes in our trials (1109 ml – 15,320 ml), correction for baseline 
volume by using proportional change is more appropriate when investigating volume 
changes. Proportional change is also commonly used in ADPKD studies that include 
kidney volume as an outcome.23   
We identified elevated alkaline phosphatase (ALP) as an independent predictor for 
liver volume response in PLD (chapter 5). ALP has been investigated in several other 
liver diseases. One study showed that high ALP level acts as a surrogate biomarker for 
worse prognosis in primary sclerosing cholangitis, whereas in another study decreasing 
ALP resulted in improved survival in primary biliary cirrhosis patients treated with 
ursodeoxycholic acid.24, 25 These findings underline the role of ALP as a biomarker in liver 
diseases. Our results suggest that ALP can act as a prognostic biomarker in PLD patients 
requiring somatostatin analogues. We speculate that ALP status can assist in the decision 
whether to start somatostatin analogue therapy in these patients.  
Both octreotide 40 mg and lanreotide 120 mg demonstrated comparable efficacy in 
reducing liver volumes in our studies. Although formal comparative studies are lacking in 
PLD, our results are in line with studies that evaluated somatostatin analogues in patients 
with acromegaly, which demonstrated similar effects of octreotide and lanreotide.26, 27 
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Implications
Somatostatin analogues are effective in attenuating polycystic liver and kidney growth and 
reducing symptoms in ADPKD, and can therefore be used to treat ADPKD patients with 
highly symptomatic PLD who are ineligible for surgical therapies. Whether SA therapy is 
effective and safe in patients with end-stage renal disease needs to be investigated. 
Based on our findings, there is no preference for a specific type of somatostatin analogue 
(lanreotide 120 mg or octreotide 40 mg) when treating PLD patients. Although only a 
formal randomized trial can definitely conclude which somatostatin analogue type 
is more effective in PLD, we believe that this thesis provides enough evidence for this 
recommendation. One study showed that a lower dose of lanreotide (90 versus 120 mg) 
was also effective in reducing liver volume, although less pronounced.28 We therefore 
recommend using the somatostatin analogue doses used in the clinical randomized trials.
Especially young women with PLD are at risk for a progressive disease course. This 
provides extra support for the avoidance of additional risk factors such as exogenous 
estrogens for young female PLD patients. Given the efficacy of somatostatin analogues 
in this subgroup, one could consider starting therapy in young women with symptomatic 
PLD in clinical practice, especially when they have an elevated ALP. Before starting 
somatostatin analogues, clinicians must first become familiar with side-effects and 
guidelines of prescribing these drugs in patients with PLD, and have the facilities to 
perform liver volumetry. In addition, our results only apply for a treatment period of 6-12 
months, although two extension trials showed that prolonging somatostatin analogue 
therapy resulted in maintenance of the effect up to 2 years. 5, 8, 9, 29 Discontinuation 
resulted in immediate recurrence of liver growth, indicating that continuous treatment 
will be necessary to maintain the beneficial effect.29 
 
Reflection
The main strength of this thesis was that we included the individual patient data of all 
published trials evaluating long-acting somatostatin analogue therapy in PLD patients. 
We only included data from prospective studies, which is less sensitive for bias compared 
with retrospectively collected data. The collaboration and sharing of data with other 
international research groups maximized the number of patient numbers in our 
studies, which increased the power of our analyses. PLD is a rare disease, therefore the 
collaboration with other centers is essential to be able to design and execute the studies 
described in this thesis.
We used an observational trial design to evaluate the effect and safety of lanreotide 
in ADPKD patients. Although this trial confirmed the results in other studies, it was of 
limited added value to current existing evidence. One could consider the choice for an 
observational design as a limitation, because it is difficult to draw definite conclusions 
without a control and treatment effects may be overestimated. We believe that the 
inclusion of a control group would not be ethical, because there already was evidence that 
lanreotide reduced liver and kidney volumes in a small group of patients with ADPKD.5 
In my opinion, an observational design was more appropriate than a formal placebo-
controlled trial to investigate effects and safety of somatostatin analogues in this specific 
subgroup of patients. However, the short follow-up period of 6 months and strict inclusion 
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and exclusion criteria limited the novelty of our observational study. By including patients 
with end-stage renal disease, we could obtain more information on safety and effect of 
somatostatin analogues in certain patient groups that were excluded in the original trials. 
By extending the time of follow-up we would be able to draw conclusions on effects and 
safety beyond 6 months. 
We used a non-validated generic gastrointestinal questionnaire to measure (changes in) 
PLD-related symptoms in most studies.30 This questionnaire is probably less responsive to 
the specific nature of PLD and is therefore limited in detecting effect of SAs on symptoms 
in PLD. Unfortunately, a standard validated questionnaire that scores PLD-related 
symptoms in patients with ADPKD or PCLD was not available at the start of these studies.
Future perspectives
The results of clinical trials in PLD suggest that lifelong treatment with somatostatin 
analogues might be necessary to maintain its effects. It is therefore most important 
to determine whether the beneficial effects in young women and safety profiles are 
maintained with long-term therapy, especially given the considerable costs of this 
treatment and the risk for developing cholelithiasis after prolonged treatment with 
somatostatin analogues.31, 32 The DIPAK trial evaluates the effect of lanreotide in 300 
ADPKD patients over a time period of 3 years and includes a considerable group of 
patients with PLD. These results of this study will provide more insight in the long-term 
efficacy and safety of lanreotide in PLD.33     
Future studies should focus on enhancing the efficacy of somatostatin analogues. 
Attempts to increase efficacy by adding the mTOR-inhibitor everolimus unfortunately 
failed.7 Pasireotide is a novel multireceptor synthetic somatostatin analogue.34 In 
contrast to lanreotide and octreotide, it binds with high affinity to all somatostatin 
receptors except for somatostatin receptor 4.35 The SOM230 study currently investigates 
the efficacy of pasireotide in patients with severe PLD (NCT01670110). The further 
unraveling of molecular mechanisms in hepatic cystogenesis will aid in the identification 
of new therapeutic strategies.36 This had led to the discovery of ursodeoxycholic acid as 
a potential medical therapy for PLD, which is currently being investigated in the CURSOR 
trial (NCT02021110). 
Little is known about the progression and consequence of hepatomegaly in PLD patients. 
We should prospectively investigate prognosis of individual PLD patients, in order 
to identify patients with worse prognosis that require therapy. Endpoints of interest 
would be symptoms, complications, liver volume and therapies. Ideally, the study will 
be a large long-term prospective cohort running in multiple international centers. This 
study will enable us to answer important clinical research questions, such as the role of 
postmenopausal status in PLD progression and risk factors for massive hepatomegaly 
in men. Finally, we can use this study design to further explore the role of alkaline 
phosphatase as a prognostic biomarker in treated and untreated PLD patients.  
While our volumetry method (manual segmentation) accurately calculates liver volumes, 
it is also very time-consuming. We should therefore develop automatic volumetry 
methods that can measure liver volumes quickly, accurately and with good reproducibility. 
A recent study used ellipsoid equation to reliably estimate total kidney volumes in ADPKD 
patients.37 This procedure can possibly be adapted in order to estimate liver volumes 
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in PLD. In addition, we should improve current volumetry techniques so that they can 
determine liver cyst volumes in addition to total liver volumes. This will enable us to 
investigate how drug therapies affect different tissues in the polycystic liver.   
It remains an important issue that the indication for treating PLD patients is dictated 
by symptoms rather than by liver volume per se. It is still unknown to which extent 
progression in liver volumes results worsening of symptoms and quality of life, and vice 
versa which reduction in liver volume translates into significant clinical improvement. 
Unfortunately, current gastrointestinal symptom questionnaires lack specificity for PLD as 
they also include items that are irrelevant and do not address extra-abdominal symptoms 
in PLD, which makes it difficult to investigate the relationship between liver volume and 
clinical improvement. Recently, a tool is developed which is more sensitive to changes in 
PLD-specific symptoms than the generic SF-36.38 This patient-reported outcome tool can 
be utilized in future studies to evaluate the efficacy of (experimental) therapies and to 
define clinical response in patients receiving somatostatin analogue therapy.
RESEARCH AGENDA
•EVALUATE LONG –TERM EFFICACY AND SAFETY OF SOMATOSTATIN ANALOGUES IN PLD 
•INVESTIGATE THE EFFICACY OF PASIREOTIDE IN CLINICAL TRIALS
•FURTHER EXPLORE MOLECULAR MECHANISMS IN HEPATIC CYSTOGENESIS TO IDENTIFY NEW 
THERAPEUTIC STRATEGIES
•FOLLOW THE NATURAL COURSE OF PLD PATIENTS AND IDENTIFY PATIENTS AT RISK FOR WORSE 
PROGNOSIS
•INVESTIGATE THE ROLE OF ALKALINE PHOSPHATASE AS A PROGNOSTIC BIOMARKER IN 
TREATED AND UNTREATED PLD PATIENTS
•DEVELOP FAST AND ACCURATE METHODS TO MEASURE TOTAL LIVER AND LIVER CYST VOLUME 
PROGRESSION
•UTILIZATION OF A PLD-SPECIFIC PATIENT-REPORTED OUTCOME TOOL IN FUTURE STUDIES 
•DEFINE CLINICAL RESPONSE IN PLD PATIENTS RECEIVING SOMATOSTATIN ANALOGUE THERAPY
99
General Discussion
6
References
1. Drenth JP, Chrispijn M, Nagorney DM, et al. Medical and surgical treatment options for polycystic 
liver disease. Hepatology 2010;52:2223-2230.
2. Schnelldorfer T, Torres VE, Zakaria S, et al. Polycystic liver disease: a critical appraisal of hepatic 
resection, cyst fenestration, and liver transplantation. Ann Surg 2009;250:112-118.
3. Temmerman F, Missiaen L, Bammens B, et al. Systematic review: the pathophysiology and 
management of polycystic liver disease. Aliment Pharmacol Ther 2011;34:702-713.
4. van Keimpema L, Nevens F, Adam R, et al. Excellent survival after liver transplantation for isolated 
polycystic liver disease: an European Liver Transplant Registry study. Transpl Int 2011;24:1239-1245.
5. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic 
liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009;137:1661-1668.
6. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin 
analogue octreotide. Clin JAm Soc Nephrol 2010;5:783-789.
7. Chrispijn M, Gevers TJ, Hol JC, et al. Everolimus does not further reduce polycystic liver volume when 
added to long acting octreotide: Results from a randomized controlled trial. J �Hepatol 2013;59:153-
159.
8. Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: 
results after 2 years. Nephrol Dial Transplant 2012;27:3532-3539.
9. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for 
autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-1061.
10. van Keimpema L, Drenth JP. Effect of octreotide on polycystic liver volume. Liver Int. 2010;30:633-
634.
11. Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst 
growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-
controlled, multicentre trial. Lancet 2013;282:1485-1495.
12. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in 
autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68:206-216.
13. Buitinga L, Braakman-Jansen LM, Taal E, et al. Comparative responsiveness of the EuroQol-5D and 
Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis 
factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis care & 
research 2012;64:826-832.
14. Johnsen LG, Hellum C, Nygaard OP, et al. Comparison of the SF6D, the EQ5D, and the oswestry 
disability index in patients with chronic low back pain and degenerative disc disease. BMC 
musculoskeletal disorders 2013;14:148.
15. Hogan MC, Abebe K, Torres VE, et al. Liver Involvement in Early Autosomal-Dominant Polycystic 
Kidney Disease. Clin Gastroenterol Hepatol. 2015;13:155-164.
16. Wijnands TF, Neijenhuis MK, Kievit W, et al. Evaluating health-related quality of life in patients 
with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 
2014;34:1578-1583.
17. Sallee M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic 
kidney disease. Clin J Am Soc Nephrol 2009;4:1183-1189.
18. Tocchi A, Costa G, Lepre L, et al. The influence of somatostatin on bacterial translocation. Panminerva 
medica 2001;43:11-14.
19. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey 
on a large series of acromegalic patients. J Endocrinol Invest 2008;31:704-710.
20. Qian Q, Li A, King BF, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 
2003;37:164-171.
21. Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for the development of hepatic cysts in 
autosomal dominant polycystic kidney disease. Hepatology 1990;11:1033-1037.
22. Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates 
hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 
1997;26:1282-1286.
23. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic 
kidney disease. N Engl J Med 2012;367:2407-2418.
24. Lindstrom L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline 
phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol 
Hepatol 2013;11:841-846.
25. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis 
and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715-720.
26. Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects 
of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with 
acromegaly. Clin Endocrinol (Oxf) 2008;68:473-480.
27. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide 
Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J 
Endocrinol 2004;150:489-495.
28. Temmerman F, Gevers T, Ho TA, et al. Safety and efficacy of different lanreotide doses in the 
treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol 
Ther 2013;38:397-406.
100
Chapter 6
29. Chrispijn M, Nevens F, Gevers TJ, et al. The long-term outcome of patients with polycystic liver 
disease treated with lanreotide. Aliment Pharmacol Ther 2012;35:266-274.
30. Bovenschen HJ, Janssen MJ, van Oijen MG, et al. Evaluation of a gastrointestinal symptoms 
questionnaire. Dig Dis Sci 2006;51:1509-1515.
31. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol 
Hepatol 2013;10:101-108.
32. Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of 
gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-
188.
33. Meijer E, Drenth JP, d’Agnolo H, et al. Rationale and Design of the DIPAK 1 Study: A Randomized 
Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal 
Dominant Polycystic Kidney Disease. Am J Kidney Dis 2014;63:446-455.
34. Weckbecker G, Briner U, Lewis I, et al. SOM230: a new somatostatin peptidomimetic with potent 
inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and 
dogs. Endocrinology 2002;143:4123-4130.
35. Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin 
receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009;94:654-661.
36. Wills ES, Roepman R, Drenth JP. Polycystic liver disease: ductal plate malformation and the primary 
cilium. Trends Mol Med 2014;20:261-270.
37. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging Classification of Autosomal Dominant Polycystic 
Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials. J Am Soc Nephrol. 
2015;26:160-172.
38. Temmerman F, Dobbels F, Ho TA, et al. Development and validation of a polycystic liver disease 
complaint-specific assessment (POLCA). J Hepatol 2014;61:1143-1150.
101
General Discussion
6
 
 v
Chapter 7
Summary and Acknowledgements
104
Chapter 7
English Summary
Polycystic liver disease (PLD) is characterized by the formation of multiple benign cysts 
in the liver. It is associated with two inherited disorders: combined with polycystic 
kidneys in autosomal dominant polycystic kidney disease (ADPKD) and isolated in 
autosomal dominant polycystic liver disease (PCLD). The natural course of PLD shows 
a continuous growth in number and size of hepatic cysts. Although liver function is 
preserved, the massive enlarged liver can result in mechanical complaints, including 
abdominal distension, pain, and early satiety. Currently available treatment options are 
mainly invasive and are aimed at surgical reduction of liver volume in order to ameliorate 
symptoms. These therapies are successful in selected patients. However, they can cause 
significant morbidity and mortality, and most importantly, are unable to change the 
natural course of the disease. 
This has led to the introduction of somatostatin analogues as a treatment option for 
PLD. Somatostatin analogues, including lanreotide and octreotide, are cyclic adenosine 
monophosphate (cAMP) inhibitors and decrease hepatic cyst volumes. In the last few 
years, several trials have demonstrated that somatostatin analogues reduce polycystic 
liver volumes in patients with PLD (chapter 2). These observations clearly support the 
thesis that growth of polycystic livers can be suppressed by somatostatin analogues. 
However, there are still some issues that need to be resolved before somatostatin 
analogues can be used in daily practice. A more pronounced side-effect profile can 
possibly off-set potential benefits of therapy and limits its use in clinical practice. In 
addition, it is too costly to prescribe somatostatin analogues to every patient with PLD. 
Given the overall modest effect of somatostatin analogues in trials, it is paramount to 
investigate whether there are subgroups of PLD patients who will benefit more from this 
therapy.
In this thesis, we investigated several patient factors (age, gender), disease characteristics 
(liver size, underlying diagnosis, lab abnormalities) and treatment variables (somatostatin 
analogue type) that may affected outcomes in PLD patients receiving somatostatin 
analogue therapy. These findings will help us to prevent unnecessary or ineffective 
somatostatin analogue therapy in PLD patients, as well as individualizing treatment 
strategies.
To investigate the safety and effect of somatostatin analogue therapy in ADPKD patients 
with PLD, we performed an observational trial that evaluated 6 months of lanreotide in 43 
ADPKD patients with polycystic livers (chapter 3a & 3b). Patients had reduced polycystic 
liver and kidney volumes and decreased gastro-intestinal symptoms after 6 months of 
lanreotide treatment, with an acceptable side-effect profile. However, we did not find an 
effect on quality of life in this study. Our results suggest that lanreotide therapy can be 
used to treat symptomatic PLD in ADPKD patients.
In chapter 4 we investigated whether certain subgroups of PLD patients would benefit 
more from somatostatin analogue therapy. We pooled the individual patient data of all 
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randomized placebo-controlled trials that evaluated somatostatin analogues in PLD and 
had liver volume as the primary outcome. Key findings of our meta-analysis were that 
underlying diagnosis (ADPKD or PCLD) and liver size had little influence on efficacy of 
somatostatin analogues in PLD patients. Particularly placebo-treated young women (48 
years old and younger) showed the largest increase in polycystic liver volume (+4.8%) and 
responded best to somatostatin analogue therapy (-8.0%) when compared with placebo. 
Based on these results, one could consider to start somatostatin analogue therapy in 
young women with PLD.
Finally, to identify which factors predict response in PLD patients during somatostatin 
analogue therapy (chapter 5), we pooled the individual patient data of 4 trials (n = 153). 
Elevated alkaline phosphatase at baseline was an independent predictor for liver volume 
response in PLD patients treated with somatostatin analogues, but  did not predict 
kidney volume response. Our findings suggest that alkaline phosphatase could serve as a 
prognostic biomarker in PLD patients requiring somatostatin analogue therapy. It remains 
unclear whether elevated alkaline phosphatase also predicts liver volume reduction in 
untreated PLD patients. 
These findings confirm the efficacy of somatostatin analogues in different patient groups 
with PLD, and show that outcomes in PLD can be affected by patient factors (young 
women) and disease characteristics (alkaline phosphatase). Future studies should focus 
on patient reported outcomes in PLD, as the main goal of treatment is to improve the 
quality of life of these patients. Furthermore, since PLD is a chronic condition, it is 
paramount to confirm the long-term efficacy and safety of somatostatin analogues.
English summary
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Nederlandse Samenvatting
Polycysteuze leverziekte (PLD) wordt gekenmerkt door de vorming van multipele 
goedaardige cysten in de lever. Het komt met name voor bij twee erfelijke aandoeningen: 
in combinatie met polycysteuze nieren bij autosomaal dominant polycysteuze nierziekte 
(ADPKD) en als een geïsoleerde polycysteuze lever bij autosomaal dominante polycysteuze 
leverziekte (PCLD). Het natuurlijk beloop van PLD toont een continue groei in grootte en 
aantal van levercysten. Hoewel de leverfunctie gespaard  blijft, kan de massaal vergrote 
lever leiden tot mechanische klachten, zoals een uitgezette buik, pijn en snelle verzadiging. 
De op dit moment beschikbare behandelingen zijn voornamelijk chirurgisch en gericht 
op volumereductie van de lever ter vermindering van klachten. Deze behandelingen zijn 
succesvol bij sommige patiënten. Ze kunnen echter aanzienlijke complicaties en sterfte 
veroorzaken en, het belangrijkst, ze zijn niet in staat zijn om het natuurlijke beloop van 
de ziekte te veranderen. Dit heeft geleid tot de introductie van somatostatine analogen 
als behandelingsoptie voor PLD. Somatostatine analogen, zoals octreotide en lanreotide, 
kunnen het levercyste volume verminderen door cyclisch adenosine monofosfaat 
(cAMP) te remmen. Verschillende studies hebben in de afgelopen jaren aangetoond dat 
somatostatine analogen inderdaad het polycysteuze levervolume kunnen reduceren in 
PLD patiënten (hoofdstuk 2). Deze waarnemingen ondersteunen duidelijk de stelling dat 
de groei van polycysteuze levers kan worden onderdrukt door somatostatine analogen.
Er zijn echter nog enkele problemen die moeten worden opgelost voordat somatostatine 
analogen kunnen worden gebruikt in de dagelijkse praktijk. Een meer uitgesproken 
bijwerkingenprofiel kan een eventueel voordeel van de behandeling teniet doen. 
Bovendien is het te duur om alle PLD patiënten somatostatine analogen voor te schrijven. 
Gezien het gemiddelde effect van somatostatine analogen in studies bescheiden is, is het 
van groot belang te achterhalen of er subgroepen van PLD patiënten zijn die meer baat 
hebben bij deze therapie. 
In dit proefschrift onderzocht ik verschillende patiëntfactoren (leeftijd, geslacht), 
ziektekenmerken (grootte van de lever, onderliggende aandoening, laboratorium 
afwijkingen) en behandelingsvariabelen(somatostatine analoog type) die mogelijk 
uitkomsten kunnen beïnvloeden bij PLD patiënten die behandeld worden met 
somatostatine analogen. Deze bevindingen zullen ons helpen om onnodige of ineffectieve 
therapie met somatostatine analogen in PLD patiënten te voorkomen, en zal zorgen voor 
verdere individualisatie van behandelstrategieën.
Om de veiligheid en het effect van somatostatine analogen bij ADPKD patiënten met PLD 
te onderzoeken, voerde ik een observationele trial uit waarin wij 6 maanden behandeling 
met lanreotide evalueerde in 43 ADPKD patiënten met een polycysteuze lever (hoofdstuk 
3a & 3b). Patiënten hadden afgenomen polycysteuze lever- en niervolumes en minder 
gastro-intestinale symptomen na 6 maanden behandeling met lanreotide, met een 
acceptabel bijwerkingenprofiel. We hebben echter geen effect op de kwaliteit van leven 
gevonden. Deze resultaten suggereren dat lanreotide therapie kan worden gebruikt om 
ernstig symptomatische PLD in ADPKD patiënten te behandelen.
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In hoofdstuk 4 heb ik onderzocht of bepaalde subgroepen van PLD patiënten beter 
reageren op somatostatine analoog behandeling. Ik heb de individuele patiëntgegevens 
samengevoegd van alle gerandomiseerde placebogecontroleerde studies die de 
effectiviteit van somatostatine analogen hebben onderzocht in PLD patiënten, en 
levervolume als belangrijkste uitkomst hadden. Deze meta-analyse liet zien dat 
onderliggende diagnose (ADPKD of PCLD) en levergrootte weinig invloed hadden op 
effectiviteit van somatostatine analogen in patiënten met PLD. Met name jonge vrouwen 
(48 jaar en jonger) behandeld met placebo lieten de grootste stijging in polycysteuze 
lever volume (+ 4,8%) zien en reageerden het best op somatostatine analoog behandeling 
(-8,0%). Gebaseerd op deze resultaten kan men overwegen jonge vrouwen met PLD te 
behandelen met somatostatine analogen.
Tenslotte heb ik de individuele patiëntgegevens van 4 studies (n = 153) samengevoegd om 
te bepalen welke factoren respons voorspellen bij PLD patiënten tijdens somatostatine 
analoog behandeling (hoofdstuk 5). Een verhoogd gehalte aan alkalische fosfatase 
(een leverenzym dat verhoogd is bij PLD patiënten) bij start van behandeling was een 
onafhankelijke voorspeller voor lever-volume afname in PLD patiënten behandeld met 
somatostatine analogen, maar was geen voorspeller voor nier-volume afname. Deze 
bevindingen suggereren dat alkalische fosfatase zou kunnen dienen als een prognostische 
biomarker voor lever-volume respons in PLD patiënten die behandeld gaan worden met 
somatostatine analogen. Het blijft onduidelijk of verhoogde alkalische fosfatase ook lever 
volume afname voorspelt in onbehandelde PLD patiënten.
Deze bevindingen bevestigen de werkzaamheid van somatostatine analogen in 
verschillende patiëntengroepen met PLD, en tonen dat de response op somatostatine 
analogen kunnen worden beïnvloed door patiëntfactoren (jonge vrouwen) en 
ziektekenmerken (alkalisch fosfatase). Omdat het verbeteren van kwaliteit van leven 
in PLD patiënten het belangrijkste doel van behandeling is, zal toekomstig onderzoek 
zich meer moeten richten op patiënt gerapporteerde uitkomsten. Aangezien PLD een 
chronische aandoening is, is het noodzakelijk dat de werkzaamheid en veiligheid van 
somatostatine analogen op lange termijn bevestigd worden.
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Dankwoord
Zo, nu alle andere hoofdstukken zijn geschreven is het eindelijk tijd geworden om het 
dankwoord te schrijven. Mogelijk wel het moeilijkste hoofdstuk om te schrijven, niet in 
de laatste plaats omdat het in het Nederlands is. Maar omdat het promotieproject voor 
mij een ontzettend leuke en leerzame tijd is geweest, kom ik er niet onderuit om iedereen 
te bedanken die hieraan heeft bijgedragen. 
Allereerst wil ik alle patiënten bedanken die hebben deelgenomen aan de onderzoeken, 
zonder hen zou dit onderzoek niet mogelijk zijn. 
Prof. dr. J.P.H. Drenth, beste Joost, bedankt voor de vele kansen  en mogelijkheden die jij 
mij gegeven hebt. Hierdoor heb ik het maximale uit mijn promotietijd weten te behalen. 
Door jou heb ik een goed beeld gekregen wat het inhoudt om op hoog niveau onderzoek 
te doen. Ik heb altijd erg genoten van onze gesprekken waarin we onze visies op het PLD-
onderzoek bespraken, bij voorkeur onder het genot van een goede IPA!  Mede dankzij 
jouw snelle reacties en revisies heb ik mijn promotietraject in deze korte tijd kunnen 
afronden.
Leden van de manuscriptcommissie, Prof. dr. Bart Kiemeney, Prof. dr. Peter Pickkers en 
Prof. dr. Ulrich Beuers, hartelijk dank voor het grondig doornemen van mijn proefschrift.
Prof. dr. J.F.M. Wetzels, beste Jack, hoewel we elkaar met name gesproken hebben in 
het kader van de RESOLVE trial en DIPAK consortium, zijn je adviezen van grote invloed 
geweest op mijn onderzoek. Jouw kritische houding en reflectievermogen is een groot 
voorbeeld voor mij geweest tijdens mijn promotieonderzoek. 
Dr. M. Hogan, dear Marie, I really enjoyed my stay at Rochester in the Mayo Clinic, and 
I appreciated it that you took the time to visit places with me in the weekends. I loved 
working with you and I am glad that Myrte is in the Mayo Clinic to continue our research 
project. I am looking forward to our next sailing trip!  
I want to thank Prof. Dr. Vicente Torres, Dr. Piero Ruggenenti, Dr. Annalisa Perna, Dr. 
Anna Caroli, Dr. Frederik Nevens and Drs. Frederik Temmerman for our international 
collaboration on PLD research. We have shown that by working together we are able to 
perform high-impact research. 
Ik wil alle leden bedanken van het DIPAK consortium, en in het bijzonder Dr. Ron 
Gansevoort. Ron, ik ben onder de indruk van wat je hebt opgezet, en vind je tomeloze 
inzet voor het DIPAK consortium inspirerend. Esther, Wendy, Edwin, Niek, Folkert, 
Darius, Mahdi en Hester, ik heb mijn tijd in het consortium en tijdens de ASN meetings 
als erg leuk ervaren. 
Beste Mark, we zijn tegelijkertijd gestart met ons promotietraject en kwamen al snel op 
dezelfde kamer terecht. We wisten ons goed te vermaken, waarbij we menig radiostations 
voorbij hebben horen komen (Nashville FM?). Naast onze wetenschappelijke discussies 
hebben we vooral ook veel geouwehoerd, op werk en natuurlijk ook in de Aesculaef. Ik 
had het mooi gevonden als je je vooropleiding zou gaan volgen in het Rijnstate, helaas 
heeft het Radboud je gestrikt. Ik ben blij dat jij naast mij wilt staan als paranimf tijdens de 
verdediging van mijn proefschrift.
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Lieve Becca, wie had gedacht dat wij nog eens zouden gaan specialiseren en promoveren 
toen wij elkaar voor het eerst ontmoette tijdens de introductie van BMW? Het is een van 
mijn beste keuzes geweest om met de studie geneeskunde te starten, en het feit dat jij 
dezelfde overstap maakte gaf mij veel steun. Ik ben er trots op dat jij bij mijn verdediging 
naast mij wilt staan als paranimf.
Titus, ik weet nog dat ik op een maandagochtend van Joost kreeg te horen dat ik een 
VU student moest gaan begeleiden. Er was nog niets geregeld, dus in alle haast werd je 
overal aangemeld. Helaas had ik je achternaam niet helemaal meegekregen en stond je 
overal als Titus Brandsma in het systeem. Een goed begin is het halve werk, zeg maar. 
Gelukkig is onze samenwerking er alleen op vooruitgegaan, eerst als student en nu als 
promovendus in de PLD-groep. Ik hoop dat onze samenwerking nog lang door mag gaan, 
in het onderzoek en de kliniek. Myrte, jij zet het PLD-onderzoek dat ik heb opgezet door 
en doet dat ontzettend goed. Ik had geen betere opvolger kunnen bedenken voor het 
project in de Mayo Clinic. Nu maar hopen dat je daar de barse weeromstandigheden 
overleefd! Ik vind het leuk dat ik je mag blijven begeleiden tijdens jouw promotietraject, 
en ook bij jou hoop ik dat onze samenwerking nog lang mag duren.
Beste collega’s van de PLD groep, bedankt voor de leerzame en leuke tijd samen! Hedwig, 
Marten, Wybrich, Edgar, René, Jody, Manoe en Melissa, samen hebben we het PLD-
onderzoek op de kaart gezet. Het is mooi om te zien hoe onze onderzoeksgroep gegroeid 
is in die jaren. Daarnaast heb ik erg genoten van de werkbesprekingen, congressen, 
PCLD-dagen en voetbalmiddagen!
Naast de grote schare van PLD-onderzoekers wil ik ook mijn andere collega’s van de MDL-
afdeling bedanken.  Floor, Lauranne, Jasmijn, Jos, Angelique, Loes en Mark Broekman, 
bedankt voor alles. De pubquiz avonden waren een goede afwisseling van het onderzoek. 
Mooi dat we ook samen het ontwikkelplan voor MDL-onderzoekers opgezet hebben! 
Ik heb de eer gehad om veel studenten te mogen begeleiden tijdens hun onderzoeksstage. 
Sylvia, Titus, Marten, Myrte, Ralf, Nienke en Jeroen, ik heb ontzettend veel van jullie 
geleerd. Goed dat sommigen van jullie bij ons zijn gebleven als promovendus! Bedankt 
voor jullie hulp en inzet.
Van het lab wil ik Wilbert, Hennie, Evelyn en Wim nog bedanken. De eerste keer dat ik 
sommigen van jullie ontmoette was al tijdens mijn snuffelstage in het 1e jaar van mijn 
BMW studie. Wie had het toen gedacht dat ik ook nog terug zou komen naar de MDL! 
Hoewel het er erg fanatiek aan toe kon gaan, waren de spaarzame momenten met rikken 
altijd een goede manier van ontspannen. 
Graag wil ik mijn collega’s van de buitenhoek bedanken voor de prettige samenwerking. 
Merel, Polat, Geert, Mieke, Bjorn, Frank, Sanne en Robin, het begon daar allemaal in 
de buitenhoek, waar we mooi ons eigen plekje hadden. Leuk dat ik nu ook weer met 
sommigen van jullie samenwerk ik in het Rijnstate ziekenhuis. 
Verder wil ik uiteraard Margriet en Joanna bedanken voor de methodologische en 
statistische ondersteuning bij mijn projecten. Wietske, ik wil jou in het bijzonder 
bedanken voor de vele discussies die ik met jou gevoerd heb over ethiek van onderzoek 
en de begeleiding van studenten/promovendi. Jouw ervaring als senior-onderzoeker 
heeft mij hierbij veel geholpen.
Ik heb tijdens mijn promotie deelgenomen aan de  Radboud Da Vinci Challenge, ik wil 
Ellen van der Linden, Anja Schumann en de overige deelnemers bedanken voor deze 
geweldige ervaring. 
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Ook wil ik alle AIOS MDL, MDL stafleden, secretaresses en Jessica bedanken voor hun 
hulp en ondersteuning. In het bijzonder wil ik de dames van de dagbehandeling Karin en 
Astrid bedanken voor de gezellige praatjes en ondersteuning bij de trials, Heleen Dekker, 
Marijke en Manita van de afdeling Radiologie voor hun ondersteuning bij de CT-scans in 
het kader van de RESOLVE trial, en Ellen, Aswin Hofman en Rene Monshouwer voor hun 
hulp bij de CT-volumetrie op de radiotherapie afdeling.
Tenslotte wil ik ook alle co-auteurs die ik nog niet specifiek heb genoemd bedanken voor 
hun bijdrage aan de artikelen. 
Dan wil ik nu nog iedereen bedanken die belangrijk voor mij waren naast het werk. 
Iedereen van O.M.G. FUST, Maarten, MVDB, Matti, Bart, Miel, Joris, Becca en Sas, dank 
voor jullie vriendschap. Wat wij allemaal hebben meegemaakt tijdens onze studietijd, 
daar kun je een boek over schrijven.  Miel en Joris, jullie bedankt voor maken van 
respectievelijk de layout en de cover, het zorgt zo toch nog voor een persoonlijke touch. 
Mijn vrienden uit ‘Nisseroi’, Jorg, Joshua, Bas, Paul, Jeroen, Ayoni en Gerwin, ik zie jullie 
niet meer zo vaak, maar als ik jullie zie is het altijd ouwerwets gezellig. Ik wil ook het 
woensdag eet legioen bedanken voor de leuke etentjes, de avonden zorgen voor een 
welkome afwisseling van het drukke werk. Ik wil ook mijn gildebroeders bedanken van 
A.H.G. Senex Captiosus, ik waardeer de Academische verbreding en verdieping buiten 
de Medische wetenschappen, en de borrels zijn natuurlijk ook prima! Tenslotte wil ik de 
vrienden van Sentimeel bedanken voor de vermakelijke weekendjes weg.
Lieve pap en mam, bedankt voor de liefde, hulp en mogelijkheden die jullie hebben 
gegeven tijdens mijn leven. Jullie hebben mijn keuzes altijd gesteund, mede hierdoor sta 
ik waar ik nu sta.  Nikki en Robbert, bedankt voor de interesse die jullie hebben getoond. 
Ten tijde van mijn promotie hebben jullie Siem en Diede weten op te voeden, wat in mijn 
ogen een veel grotere prestatie is! Steffi en Tom, nu jullie ook samenwonen in Nijmegen, 
moeten we maar eens vaker afspreken. Mooi om te zien dat jij nu ook het onderzoek in 
bent gegaan Steffi.
Allerliefste Femke. Jij bent mijn grootste steun en toeverlaat. Zonder jou was dit boekje 
er nooit geweest. We hebben heel wat avonturen voor de boeg, gelukkig sta jij aan mijn 
zijde hierbij!
Omdat ik er om bekend sta mensen te vergeten, wil ik bij deze iedereen bedanken die ik 
mogelijk vergeten ben. Bedankt!
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Curriculum Vitae
Naam:   Tom Gevers
Woonplaats:   Nijmegen
Geboortedatum:  04-10-1982
Tom Gevers werd op 4 oktober 1982 geboren in Nistelrode en groeide hier op in een 
gezin met twee jongere zusjes. Na het behalen van het Atheneum diploma aan het 
Udens College te Uden, startte hij in 2001 met de studie Biomedische Wetenschappen 
aan de Radboud Universiteit Nijmegen (RUN). Tijdens het afronden van deze studie 
startte hij met de studie Geneeskunde in 2007, ook aan de RUN.
Na het behalen van zijn artsexamen in juli 2011 is Tom begonnen met zijn 
promotieonderzoek,  waarin hij de toepassing van somatostatine analogen bij patiënten 
met polycysteuze leverziekte onderzocht onder supervisie van zijn promotor prof. 
J.P.H. Drenth. Tijdens zijn promotieonderzoek heeft hij het Radboud Da Vinci talent 
programma gevolgd en heeft hij 2 maanden in de Mayo Clinic (Rochester, MI, USA) 
gewerkt. 
In het kader van zijn opleiding tot Maag- Darm- Leverarts, begon Tom op 1 juli 2014 aan 
zijn vooropleiding Interne Geneeskunde in het Rijnstate ziekenhuis te Arnhem (opleider 
dhr. dr. Louis Reichert).
Tom woont samen met zijn verloofde Femke Brants in Nijmegen, en ze gaan later dit 
jaar trouwen.   
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